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Structure of the thesis  
 
The present work is organized as follows. As my thesis consists of 2 parts of work with 
distinct foci, I chose to describe the use of MNBs/AdhVEGF complexes for cardiac 
regeneration first, whereas my work on the application of matrigel for cardiac 
regeneration forms the content of a second part. The introduction gives an overview on 
the pathology of ischemic heart disease as well as the approaches of regenerative 
medicine, thus providing the link between both parts of my work. In material & methods, 
2.1-2.21, and 2.26, describe experiments of the first part (MNBs/AdhVEGF complexes 
for cardiac regeneration), while in 2.16, 2.18, 2.19, and 2.22-2.26, the second part 
(matrigel for cardiac regeneration) is described. Results of the first part are included in 
chapter 3.1-3.14, and results from the second part are described in chapter 3.15-3.18. The 
discussion of MNBs/AdhVEGF complexes for cardiac regeneration can be found in 
chapter 4.1, and chapter 4.2 contains the discussion of matrigel for cardiac regeneration. 
Finally, conclusions are drawn from the entire body of work and, again, an overview is 
given on the whole subject of my work.  
 x 
Zusammenfassung  
 
Der Herzinfarkt stellt eine irreversible Schädigung des Herzmuskels dar. Große Infarkte 
bewirken komplexe Umbauprozesse im Gewebe der Ventrikel. Diese Veränderungen 
können die ventrikuläre Funktion beeinträchtigen und werden als ventrikuläres 
Remodelling bezeichnet. Das Remodelling führt schließlich zur progressiven Dilatation 
des linken Ventrikels und zum Herzversagen. Daher stellen die Begrenzung und 
Regeneration der myokardialen Schädigung eine große Herausforderung in der klinischen 
Forschung dar. Ansätze, die auf Gentherapie und Tissue Engineering basieren, spielen für 
die regenerative Therapie nach Myokardinfarkt eine wichtige Rolle.  
 
Die Gentherapie des Myokardinfarkts wird in Grundlagenforschung sowie präklinischen 
Forschungsprojekten bereits häufig genutzt. Insbesondere der vaskuläre endotheliale 
Wachstumsfaktor (vascular endothelial growth factor, VEGF) spielt eine wichtige Rolle 
bei der Regeneration des Herzens nach Myokardinfarkt. Diesbezüglich könnte die 
intravenöse Applikation therapeutischen Genmaterials eine für die Klinik besser 
geeignete Option darstellen als die gängige intramyokardiale Applikation. Erstere 
Methode weist jedoch Limitiationen auf - es lassen sich beispielsweise nur geringe 
Konzentrationen des Genmaterials im Herzgewebe erreichen. Daher kam in der 
vorliegenden Arbeit eine neue Technik zum Einsatz, nämlich der magnetfeldverstärkte 
Gentransfer in das kardiovaskuläre System, der ein hohes Potential für rasche und 
effiziente Gentransduktion zeigte. Die Kopplung magnetischer Nanopartikel (magnetic 
nanobeads, MNBs) an adenovirale Vektoren, die für humanes VEGF kodieren (AdhVEGF), 
erhöhte die Genexpression nach systemischer Gabe und gleichzeitigem Targeting auf das 
infarzierte Myokard durch einen extern aufgesetzten Magneten deutlich. Dies führte zu 
Neovaskularisierung und verbesserter Erholung der Funktion des linken Ventrikels nach 
dem Infarkt. 
 
Die intravenöse Applikation von Genmaterial mit Hilfe von Magnetnanopartikeln könnte 
somit eine wichtige, nicht-invasive Strategie für die Gentherapie zur Heilung der 
 xi 
ischämischen Herzerkrankung darstellen und zukünftig in der klinischen Anwendung 
eine bedeutende Rolle spielen.  
 
Die extrazelluläre Matrix (ECM) spielt eine wesentliche Rolle bei der Regulation 
zellulärer Prozesse wie etwa der Proliferation und Differenzierung von Stammzellen. 
Matrigel, eine künstliche ECM, die neben einer Anzahl extrazellulärer 
Matrixkomponenten auch Wachstumsfaktoren enthält, zeigte eine vielversprechende 
Wirkung bei der Behandlung des Herzinfarktes. Die vorliegende Arbeit belegt, dass 
Matrigel die Angiogenese im Myokard nach ischämischer Schädigung anregt und das 
Remodelling des Myokards vermindert.  
 
Intrakardiale Injektion von Matrigel milderte den Verlust an Wandstärke und verstärkte 
die Neovaskularisierung in der Infarktzone, zudem vermittelte sie eine Rekrutierung von 
c-kit+
 
und CD34+ Stammzellen in das ischämische Herzgewebe und verbesserte so 
schließlich die linksventrikuläre Funktion.  
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Summary 
 
Myocardial infarction (MI) is an irreversible injury of the heart muscle leading to 
complex changes in ventricular construction. These changes can affect ventricular 
function in a process called ventricular remodelling. Ultimately, ventricular remodelling 
causes the progressive dilatation of the left ventricle (LV) resulting in heart failure. 
Hence, the reduction and repair of myocardial damage are great challenges in clinical 
research. Therapeutic gene based approaches and tissue engineering play important roles 
in regenerative therapy after MI. 
 
Gene therapy for treatment of MI has been widely used in basic and preclinical research. 
Especially vascular endothelial growth factor (VEGF) plays an important role in 
cardiac regeneration after MI. Intravenous delivery of therapeutic genes as a non-invasive 
way of administration has been considered for clinical therapy. However, this method has 
drawbacks such as low gene concentration at the target area. In the present study, a novel 
technique of magnetic force-enhanced gene delivery to the cardiovascular system showed 
great potential for rapid and efficient transduction. In a rat MI model, systemic delivery 
of magnetic nanobeads (MNBs)/adenoviral vectors (Ad) encoding human VEGF 
(AdhVEGF) complexes under external magnetic guidance could increase VEGF expression 
in the infarcted myocardium, leading to neovascularization and improving post-infarction 
recovery of LV function. Intravenous MNB based delivery of therapeutic genes may be a 
useful, non-invasive gene therapy strategy for ischemic heart disease healing in patients 
bearing great potential for clinical application. 
 
The extracellular matrix (ECM) plays a dominant role in regulating cellular processes, 
such as proliferation and differentiation of stem cells. Matrigel as an engineered ECM 
contains a considerable amount of ECM components as well as growth factors and 
showed great promise in the treatment of MI. My research proves that matrigel promotes 
angiogenesis in the myocardium after ischemic injury and prevents remodelling of the 
myocardium. Intracardiac matrigel injection attenuated the decrease of infarct wall 
thickness, promoted neovascularization in the infarct area, mediating c-kit+ and CD34+ 
 xiii 
stem cell recruitment to the ischemic myocardium, and finally improved left ventricular 
function. 
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1       Introduction 
1.1     Ischemic heart disease 
1.1.1   Myocardial infarction 
The clinical and diagnostic establishment the term MI took place about 100 years ago and 
was published almost simultaneously by two Russian scientists, Obraztsov and Strazhesko in 
a German journal (1910) 
1
. MI is the irreversible injury and subsequent necrosis along a 
transmural wavefront from subendocardium to subepicardium due to severe and accentuated 
reduction in coronary perfusion. This specific pattern of cardiomyocyte death was named the 
wave-front phenomenon 
2
. Transmural MI of the anterior wall leads to complex changes in 
ventricular construction including both necrotic and non-necrotic areas. These changes can 
affect ventricular function by the so-called ventricular remodelling. Ventricular remodelling 
and dilatation caused by MI occur in a continuum that starts with ventricular expansion of the 
necrotic area alone. Dilatation then continues at the expense of the contractile segment by 
volume overload hypertrophy in response to increased wall tension. In the chronic phase, this 
remodelling progress of the infarction area will persist for a prolonged time period. Whereas 
there is no further expansion during the scar-forming process, the contractile segment 
elongates because of the hypertrophy. Finally, ventricular remodelling causes the progressive 
dilatation of the LV and heart failure. Ventricular aneurysm is another complication which 
may arise from the progression of infarction. An aneurysm can accentuate LV dysfunction, as 
it is “a systolic or diastolic deformation of the ventricular wall, including the akinetic-
dyskinetic necrotic area.” 3 The aneurysm aggravates the systolic dysfunction and in some 
cases worsens the secondary mitral failure. 
 
MI causes the ischemic zone to change from a state of active systolic shortening to one of 
passive diastolic lengthening in only 60 seconds 
4
. If coronary occlusion is removed less than 
20 minutes after onset, tissue viability is preserved and the resulting cellular damage and 
depression of cell function are transient. Furthermore, reperfusion of the infarcted area allows 
for the salvage of variable amounts of myocardium 
5
. After 40 minutes of ischemia followed 
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by reperfusion, 60%-70% of the ultimate infarct is salvageable. However, after 3 hours of 
occlusion, this phenomenon decreases significantly to 10%. 
 
Acute coronary occlusion can cause three states of impaired myocardium: infarcted, 
hibernating, and stunned (Figure 1). MI can cause irreversible myocardial cell death 
resulting from prolonged ischemia. Hibernating myocardium shows persistent LV 
dysfunction due to a reduced coronary blood flow, but myocardial viability can be preserved. 
Because of the lowered metabolism and hypoperfusion, hibernating myocardium has 
compromised contractility. This down-regulation of LV function at rest is a protective 
mechanism resulting from decreased oxygen consumption in the heart to secure myocyte 
survival. It has been proven that the hibernating myocardium may recover to normal if a 
normal myocardial oxygen supply-demand relationship is re-established 
6, 7
. Stunned 
myocardium is a syndrome of contractile dysfunction, but myocardial cells retain viability 
following revascularization after an ischemic episode. The most likely mechanism of 
myocardial stunning includes the generation of free oxygen radicals, calcium overload, 
structure changes of contractile protein 
8
, extracellular collagen matrix damage and reduced 
sensitivity of myofilaments to calcium 
9-11
. In summary, infarcted myocardium may develop 
if the ischemia is severe and prolonged; if a chronical LV dysfunction leads to a reduced 
blood supply but myocytes, still receive enough oxygen to remain viable, then the 
myocardium is described as hibernating myocardium. The stunned myocardium consists of 
viable cells that are acutely dysfunctional after reperfusion 
4
. 
 
Myocardial reperfusion is the restoration of coronary blood flow, either spontaneously or 
therapeutically induced, after a period of coronary occlusion 
5
. Restoration of blood flow to 
the ischemic myocardium offers the best chance for salvage following MI. Thrombolytic, 
percutaneous transluminal coronary artery bypass surgery, and coronary angioplasty have 
reduced the morbidity and mortality associated with MI significantly. Although reperfusion 
has the potential to salvage ischemic myocardium, a wide range of side effects may result 
from reperfusion including not only reversible, functional changes, but also irreversible 
injury.  
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Figure 1: Cardiac remodelling following MI: Hyperkinesis and hypertrophy of the non-
infarcted myocardium are early and late compensatory mechanisms in MI, respectively. The 
infarct region (exemplified as a dark staining of the myocardium) is characterized by reduced 
contractility (arrowheads vs. full arrows), and then wall thinning. The compensatory 
hyperkinesis (full arrows) in the non-infarcted myocardium stimulates hypertrophy 
(exemplified by thickening of the wall and double-headed arrows in the myocardial wall). 
Thick arrows highlight the potential evolution of the remodelling process over time. In the 
early and late phase after MI, the major inducers of apoptosis are listed. Neurohormones 
(angiotensin II, norepinephrine, and others) and stretch stress are major inducers of apoptosis 
not in the peri-infarct region but in the remote unaffected areas 
12
. 
 
At the pathophysiological level, myocardial reperfusion induces an intense inflammatory 
condition with activation of multiple cell types, including leucocytes and endothelial cells, 
and reduced nitric oxide bio-availability, leading to leucocyte adherence and transmigration 
of mononuclear cells 
5
. At the cellular level at least three major pathways may contribute to 
lethal reperfusion injury. Firstly, myocardial reperfusion results in massive intracellular 
calcium overload via Na
+
/H
+
 and Na
+
/Ca
2+
 exchange, which leads to mitochondrial 
calcification and contraction band necrosis. Secondly, when reperfusion provides exposure of 
the injured cardiomyocytes to a large amount of extracellular fluid, the ischemia may cause 
intracellular accumulation of osmotically active catabolites that may induce massive cellular 
sarcolemmal rupture and necrosis. Thirdly, when oxygen is reintroduced into the ischemia 
region, more cells will experience accelerated death due to oxygen free radical generation. 
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Cellular swelling and contracture lead to a “no-reflow phenomenon” that limits the recovery 
of some myocytes and possibly add to irreversible injury of other myocytes 
3, 4
. 
 
In general, although restoration of blood flow to ischemic regions is essential,
 
the 
accompanying reperfusion injury can initially worsen, rather
 
than improve myocardial 
dysfunction. The three basic types of reperfusion injury are: stunned myocardium, 
reperfusion arrhythmias, and vascular injury 
4
.  
 
1.1.2   The inflammatory response after MI 
The systemic inflammatory response consists of a humoral as well as a cell-mediated reaction. 
After MI, apoptosis of cardiomyocytes can initiate an inflammatory response to clear the 
matrix debris and necrotic cells. Finally, this phenomenon may result in the replacement of 
infarct tissue with scar tissue 
13
. Dead cells release their contents and cause an intense 
inflammatory reaction by activating the innate immune cascade and stimulating the 
complement system. On the other hand, the release of cell contents play a critical role in 
triggering the post-infarction inflammatory response by initiating the nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB) system. This mechanism results in an 
increased infiltration of leukocytes into the infarcted myocardium: The infiltrated leukocytes 
clear necrotic cells and the matrix debris and regulate metabolism by inducing growth factors 
and cytokines. The complement system can stimulate secretion of the inhibitory mediators 
such as transforming growth factor- β (TGF-β) to suppress inflammatory cytokine and 
chemokine synthesis and to remove apoptotic inflammatory leukocytes from the infarcted 
area. Furthermore, activation of TGF-β signalling promotes ECM deposition and fibroblast to 
myofibroblast transdifferentiation 
14
. Finally, neovessels acquire a muscular coat 
15
. A mature 
scar is formed including cross-linked collagen and a small cellular fraction 
16-18
. 
 
1.1.2.1 Humoral inflammatory response to MI 
Impact of the complement system in MI: The complement cascade is one essential part of 
the immune system and a major effector in a variety of immunopathological diseases. Over 
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30 proteins form this complex protein system, which may trigger a variety of biological 
activities essential for a correct immunological response. 
 
Three biochemical pathways activate the complement system: the classical complement 
pathway, the alternative complement pathway, and the mannose-binding lectin pathway 
18, 19
 
(Figure2). Research has proven that MI may initiate the complement cascade 
20
. Hill and his 
colleagues were the first researchers who have shown that leukotactic activity in the ischemic 
rat heart can be explained by the C3 cleavage product 
21
. Further studies 
20, 22
 have suggested 
that during MI, mitochondria, extruded through breaks in the sarcolemma, unfold and release 
membrane fragments which are rich of cardiolipin and protein. The subcellular fragments 
provide the components to disseminate the complement-mediated inflammatory response to 
ischemic injury by binding C1 and supplying sites for the assembly of later acting 
complement components. Messenger ribonucleic acid (RNA)  and proteins for all the 
components of the classical complement pathway are up-regulated in MI 
23
. However, a 
strong local inflammatory response has some side effects and the complement activation may 
play an important role in vascular permeability, leukocytes and mononuclear-cell chemotaxis, 
and several phagocytic processes 
24, 25
.  
 
 
 
 
 
 
 
 
 
Figure 2: Proposed scheme of the classical and alternative pathways of complement 
activation under oxidation stress caused by ischemia in the myocardium. Activation via the 
classical pathway occurs primarily as a result of immune complex formation. Immune 
complex interaction with the C1 molecule confers enzymatic activity to the C1s subunit of 
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C1. The C1 molecule cleaves C4, releasing C4a, and forms C4b, which binds to the surface 
of the target cell. C2, in association with C4b, is also cleaved by C1q, releasing C2b and 
leaving the bound C4b2a complex that possesses proteolytic activity for C3 convertase 
26
. 
 
Generation of reactive oxygen species (ROS) and the post-inflammatory response: ROS 
are chemically reactive molecules containing oxygen in the form of oxygen ions and 
peroxides. ROS are highly reactive because of the unpaired valence shell electrons. ROS are 
a byproduct of the normal metabolism of oxygen and play an important role in cell signalling 
and homeostasis 
27
. They also have harmful effects on the cells such as damage of 
deoxyribonucleic acid (DNA), oxidation reactions of polyunsaturated fatty acids (lipid 
peroxidation), oxidation reactions of amino acids in proteins and oxidative inactivation 
specific enzymes by oxidation of co-factors. Under normal circumstances, cells possess a 
substantial ability to counterbalance the generation of ROS with enzymes. Examples include 
catalases, peroxiresoxins and lactoperoxidases. However, during stress condition such as MI, 
the ROS level may increase significantly. A series of  scientific studies have shown that after 
MI/reperfusion, ROS may trigger leukotactic stimuli including complement activation 
28, 29
, 
induction of P-selectin 
30
, chemokines and cytokines upregulation through NF-κB activation 
31, 32
 and an increase of endothelial intercellular adhesion molecule (ICAM)-1 to bind to 
neutrophils 
33
. Meanwhile, it has been proven that ROS exert an inhibitory effect on 
myocardial function in vivo and play an important role in the pathogenesis of myocardial 
stunning 
24, 34-36
. 
 
Cytokines in MI: Cytokines are small cell signalling proteins that can be secreted by 
ischemic myocardium, liver and numerous cells of the immune system. A large number of 
studies 
37-39
 have proven that MI is associated with the coordinated activation of many 
cytokines such as tumor necrosis factor-alpha (TNF-α) 40, interleukin-1 37 and interleukin-
6 
41
. Complement cascade, NF-κB activation and ROS generation potently stimulate cytokine 
secretion in a series of cells including resident and blood derived cells. Especially NF-κB 
activation plays a vital role in the induction of pro-inflammatory mediators in MI/reperfusion. 
The genes regulated by NF-κB are diverse and include inflammatory, cell adhesion and 
growth factors. Under normal condition, there are very few cytokines expressed in the heart 
25
. However, they may increase up to 50 fold in the ischemic and border zone during the MI. 
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Usually, in the case of severe MI, cytokines may persist for a very long time and at high level 
in the normal adjacent myocardium. This phenomenon can cause an unfavorable contractile 
dysfunction 
25
. 
 
TNF-α: TNF-α is a cytokine involved in systemic inflammation and belongs to the group of 
cytokines that stimulate the acute phase response as in case of MI. Several studies found that 
TNF-α enhances cardiomyocyte apoptosis 42 and suppresses cardiac contractility 40, 43. 
Furthermore, Siwik and his colleagues 
44
 have proven that by stimulating TNF-α, leukocytes 
and endothelial cells can express pro-inflammatory cytokines, adhesion molecules and 
chemokines. And TNF-α regulates ECM metabolism by reducing collagen synthesis and by 
enhancing matrix metallopeptidase (MMP) activity in cardiac fibroblasts. However, some 
groups showed that TNF-α signalling has positive effects in the infarcted myocardium 45. 
Normally, TNF-α may exert distinct biological effects through the TNF receptor (TNFR) 1 
and TNFR2. Recently, investigations showed that TNFR1 medication are deleterious, 
inducing contractile dysfunction, but TNFR2 mediated action may be protective by 
attenuating adverse remodelling
46
. Obviously, TNF- α plays a much more complex role in MI 
and may explain the unpredictable effects of cytokine-targeted therapeutic strategies in 
clinical trials 
24
.  
 
The interleukin family of cytokines: Interleukins, a group of cytokines, are synthesized by 
CD4+ T lymphocytes, as well as by macrophages, monocytes and endothelial cells that 
participate in the regulation of immune responses and inflammation reactions 
47
. In the early 
phase of MI, interleukins such as interleukin-1 and interleukin-6 may activate a series of 
inflammatory proteins such as cytokines, chemokines 
48
, adhesion molecules 
49
 and colony–
stimulating factors 
17
. Through expression of chemokines and adhesion molecules, 
interleukins can infiltrate the infarcted myocardium in a targeted manner. Also, the 
interleukin signalling cascade regulates ECM metabolism and alters the MMP/tissue 
inhibitor of metalloproteinases (TIMP) balance during MI 
17
. Some research showed that 
cardiac transduction with interleukin-1Ra, an inhibitor specific for interleukin-1, significantly 
decreased infarct size and reduced the inflammatory reaction in a rat MI/ reperfusion model 
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50
, proving a side-effect role for interleukin-1 in the injured heart tissue. In contrast, another 
group demonstrated that interleukin-1 neutralization resulted in a significant increase of 
ischemic heart tissue remodelling and enhanced contractile dysfunction 
51
. Also, Wollert and 
Drexler showed that the interleukin-6 family has an attenuating effect on cardiomyocytes by 
promoting cardiac hypertrophy. Furthermore the interleukin-6 family may protect 
cardiomyocytes from apoptosis oppositely 
52
. The complete characteristic features of 
cytokines, such as overlapping or even contradictory functions, are still hampering us  to 
understand  their effects in MI injury and repair 
24
.  
 
1.1.1.2   The cellular inflammatory response to MI 
The neutrophil: Neutrophils are the most abundant type of white blood cells of mammals 
and play an important role in immune reactions. Neutrophils are recruited at the early stage 
after ischemia. Significant migration and infiltration of neutrophils may occur after 
MI/reperfusion. Endothelial adhesion molecules are induced and the permeability of the 
microvasculature is enhanced after activating inflammation response. Subsequently, a series 
of chemokines and cytokines such as interleukin-8, C5a, and leukotriene B4 are secreted by 
injured cardiac tissue. Then a variety of subsets recruit neutrophils to infiltrate the 
myocardium. Transmigration of neutrophils into infarcted myocardium requires adhesive 
molecular interactions between neutrophils and endothelium. The selectin family of adhesion 
molecules mediates the initial capture of neutrophils from the rapidly flowing blood stream to 
the blood vessel. There are three selectin molecules involved in leukocyte entry into 
myocardium, namely E-selectin (CD62E), L-selectin (CD62L), and P-selectin (GMF140, 
CD62P) 
24
.  
Upon activation, the majority of circulating neutrophils express L-selectin which plays a role 
in regulating neutrophil recruitment and rolling velocity 
53
. E-selectin is expressed by the 
cytokine-induced endothelial cells. In addition, P-selectin, stored in Weibel-Palade bodies of 
endothelial cells, can be transferred to the surface of endothelial cells rapidly mediated by 
inflammatory cytokines and chemokines. Experimental studies suggested that antibodies 
neutralizing L-selectin 
54
 and P-selectin 
55
 successfully reduced neutrophil accumulation, 
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attenuated cardiac myocyte necrosis and enhanced contractile function. In contrast, some 
experiments suggested 
56
 that P-selectin deficiency may impair neutrophil trafficking. 
Current concepts suggest that selectin may support neutrophil margination under shear stress, 
but the effects of selectin-related interventions for myocardial infarction were inconsistent 
24, 
56
.  
Obviously, rolling of neutrophils appears to be a prerequisite for stable adherence to the 
luminal endothelial cells under condition of flow, but selectin mediated adhesion of 
neutrophils necessitates another set of adhesion molecules, namely the integrins, to take part 
in and finally form a firm adhesion. Integrins are obligatory heterodimers containing two 
chains, named α (alpha) and β (beta) subunits. Neutrophil adhesion to the luminal endothelial 
cells and their transendothelial migration are dependent on β12 (CD18) subunits which are 
transported to the surface of endothelial cells as a complex 
57
. The β 12 (CD18) linked to one 
of four integrin α subunits indicated as CD11a (LFA-1), CD11b, or CD11c (p150, 95). 
CD11a/CD18 is constitutively expressed on the neutrophil membrane. The physiological 
counter ligand of the CD18 complex on the neutrophil is the intercellular adhesion 
molecule-1 (ICAM-1) which is expressed on the endothelial cell. ICAM-1 is upregulated by 
pro-inflammatory mediators such as ROS, interleukin-1, and TNF α 58, 59. Constitutive 
moderate expression of ICAM-1 levels on endothelial cells may support CD18 mediated 
adhesion and subsequent transendothelial migration. 
The neutrophil-mediated cardiomyocyte injury: Infiltrating neutrophils generate ROS and 
release enzymes contributing to the removal of dead cells and debris in the infarcted area. 
Furthermore, they can secrete chemokines including interleukin-8 and TNFα 60 to amplify 
cell recruitment. Experiments have proven that neutrophils may mediate tissue damage 
directly by the release of proteolytic enzymes 
61
. Neutrophil accumulation on the injured area 
might lead to secretion of serine proteases and release of proteinases 
62
 which are highly 
positively charged, and their cationic nature may directly alter the membrane charge 
distribution 
63
 of the injured tissue. Moreover, elastase may act by hydrolysing proteins of the 
ECM such as elastin and fibronectin 
57, 62, 64
. It has been proven that neutrophils play a 
significant role in wound healing not only through clearing dead cells and debris form 
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ischemic tissue, but also by mediating a large number of cytokines and chemokines 
57
. 
However, it has been found that neutrophils have no effects on granulation tissue formation, 
and neither do they contribute to the deposition of fibrous tissue during the healing of the 
infarcted heart 
65
. The main contribution of neutrophils to the healing response is apoptosis 
and subsequent clearance by macrophages which then secrete TGF-β 24 .  
 
Mononuclear cell infiltration: Mononuclear cells are one type of white blood cells and are 
part of the innate immune system of vertebrates. Mononuclear cells may infiltrate in infarcted 
myocardium rapidly after activation of inflammatory pathways. Research has proven that at 
an early phase after reperfusion C5a plays an important role in monocyte recruitment in the 
ischemic myocardium 
66
. At the late phase (normally 3 hours after perfusion), monocyte 
chemotactic activity largely depends on monocyte chemoattractant protein-1 and TGF-β. 
Other mediators including ROS and other CC chemokines may also play distinct roles in 
regulating monocyte infiltration. These blood derived cells will differentiate and maturate to 
macrophages after recruitment into the infarcted myocardium. Macrophage-colony 
stimulating factor and granulocyte macrophage-colony stimulating factor are crucial for 
providing the milieu necessary for monocyte differentiation 
39
. Mature macrophages play 
multiple roles in the healing process of scar formation. Firstly, they can phagocytose and 
clean debris, dead neutrophils and cardiomyocytes. Secondly, they serve as a source of 
cytokines and growth factors regulating fibroblast growth and angiogenesis 
67
. Last but not 
least, they are responsible for regulating ECM metabolism by producing MMPs and their 
inhibitors, TIMPs 
24, 68
. 
 
The mast cell: Mast cells are resident cells and may secrete abundant pro-inflammatory and 
pro-fibrotic mediators involved in wound healing. Furthermore, resident mast cells were 
detected in large numbers in the mammalian heart, mainly located in close proximity to 
vessels 
69
. Frangogiannis et al. 
70
 showed that in its early stages, mast cells may secrete 
histamine and TNF-α to regulate the inflammatory response. In the later stages, mast cells 
play a critical role in the orchestrated interaction of cytokines, growth factors and ECM 
proteins to mediate injured tissue repair. In addition, mast cells can provide a rich source of 
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cytokines and growth factors to support fibroblast proliferation 
68
. The factors responsible for 
mast cell accumulation in areas of fibrosis remain to be elucidated. Stem cell factor (SCF) is 
a potent mast cell chemoattractant that stimulates directional motility of both mucosal- and 
connective tissue type-mast cells 
68
. In addition, SCF may recruit and mediate the homing of 
bone marrow derived progenitor cells, and these cells have the ability to differentiate to 
cardiomyocytes and endothelial cells 
71-74
. Thus, SCF may be a useful cytokine for heart 
regeneration.  
Mast cell degranulation leads to the secretion of a wide range of mediators. Mast cell derived 
histamine stimulates fibroblasts and collagen synthesis 
75
. Tryptase, the most abundant of the 
proteases found in mast cell granules, induces granulocytes 
76
, stimulates fibroblast 
differentiation 
77
 and chemotaxis and upregulates type I collagen synthesis 
78
. In addition, 
mast cells are a rich source of basic fibroblast growth factor (bFGF), VEGF and TGF-β, 
which can regulate ECM metabolism, modulate endothelial cell proliferation and stimulate 
fibroblast differentiation 
24
.   
The cardiac fibroblast and myofibroblast: Fibroblasts are widely distributed connective 
tissue cells that are found in all vertebrate organisms. These mesenchymal derived cells can 
secrete a variety of ECM components such as collagen and fibronectin. Cardiac fibroblasts 
play an important role in cardiac development and remodelling as well as defining cardiac 
structure and function 
79
. Under normal conditions, resident cardiac fibroblasts have no 
contractile microfilaments or stress fibers, and secrete only minimal amounts of ECM 
components 
80
. After MI, the inflammatory milieu stimulates fibroblasts to proliferate and 
differentiate into myofibroblasts. Myofibroblasts may cover the ischemic area, accelerate the 
synthesis of ECM, and replace necrotic cardiomyocytes forming a scar. Differentiated 
myofibroblasts may be identified through their expression of α-smooth muscle actin (α-
SMA) 
81
. However, myofibroblasts express comparatively low amounts of smooth muscle 
myosin heavy chain 
82
. In contrast, during the proliferative phase, myofibroblasts produce 
interstitial collagen I and collagen III for ECM construction, and TGF β markedly increases 
ECM protein synthesis and enhances TIMP expression which promotes matrix preservation 
                                                                                                                                                                                         
                                                                                                                                                                                   Introduction                                                                                                                                                                                                                                                                             
12 
 
24
. After reconstruction of the damage, infarcted myofibroblasts undergo apoptosis. However, 
mechanisms responsible for myofibroblast apoptosis remain obscure. 
  
Vascular cell and pericyte: Angiogenesis is an important mechanism of blood vessel 
formation and it is an integral part of wound healing. Neovascularisation is essential for 
supplying necessary oxygen and nutrients to the highly dynamic and metabolically active 
cells of a healing wound 
24
. In the local environment, ECM, endothelial cells, and pericytes 
are all responsible for sustaining the balance between angiogenic factors and angiostasis 
52, 83-
86
. After MI, angiogenic growth factors including VEGF, interleukin-8 and bFGF are rapidly 
induced in the injured heart tissue 
87-89
, and play a role in increasing infarct region 
neovascularisation. The mechanisms of infarct angiogenesis remain undetermined. 
Angiogenesis starts with vasodilatation, a process involving nitric oxide. In addition, 
hypoxia-inducible factor, one of the earliest effectors of the response to ischemia, can 
activate VEGF induction and release 
90
. Vascular permeability increases in response to 
VEGF, thus allowing extravasation of plasma proteins that lay down a provisional scaffold 
for endothelial cell migration. The enhancement of permeability is mediated by the formation 
of fenestrations, vesiculo-vacuolar organelles and the redistribution of platelet endothelial 
cell adhesion molecule-1 as well as vascular endothelial cadherin 
91
. Although permeability is 
positive for angiogenesis, excessive vascular leakage has side effects such as circulation 
collapse. Angiopoietin-1, a ligand for the endothelial Tie2 receptor, is a natural inhibitor of 
vascular permeability and it can tighten pre-existing vessels. Angiopoietin-1-Tie2 signalling 
plays an important role in impeding endothelial cell activation and inhibiting the initiation of 
the angiogenic response. Furthermore, Angiopoietin-1 protects against plasma leakage 
without profoundly affecting vascular morphology 
92
. Angiopoietin-2, an endogenous 
antagonist, acts in concert with VEGF as angiogenic factors in the earliest stages of infarct 
angiogenesis through inhibiting Angiopoietin-1-Tie2 signalling. Other cytokines, including 
bFGF, TGFβ, and the ECM are important for modulating angiogenesis and take part in the 
complex process of new vessel formation after MI 
24, 93
 (Figure 3).  
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Figure 3: The cell biology of MI healing. Infarct healing is dependent on the sequential 
infiltration of the ischemic cardiac tissue with mononuclear cells, lymphocytes, neutrophils, 
mast cells, fibroblasts and vascular cells. This is a dynamic orchestrated process: 
proliferation of each cell type is followed by activation. Various cell populations have 
distinct but overlapping functions. Orchestration of the sequence of cellular events in the 
healing infarct is dependent on timely apoptosis of specific cell types. The time course 
presented here is based on a reperfused murine MI 
68
. 
 
1.1.3 The pathophysiology and mechanisms of left ventricular remodelling 
after MI 
Cardiac remodelling is a physiologic and pathologic circumstance that may occur after MI. 
Cardiac remodelling encompasses many changes including molecular, cellular and interstitial 
changes that are clinically manifested as changes in size, shape and function of the ischemic 
heart 
94
. This process is regulated by mechanical, neurohormonal, and genetic factors 
95, 96
. 
Due to MI, the acute loss of myocardium can result in an abrupt overload condition. This 
phenomenon may activate a pattern of remodelling including the infarcted border zone and 
remote non-infarcted areas. Cardiac myocyte necrosis and the resultant enhancement in load 
trigger a series of intracellular signalling pathways to modulate repair processes including 
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dilatation, hypertrophy and collagen scar formation. Cardiac remodelling can continue for 
weeks till the distending forces are counter-balanced by the tensile strength of the collagen 
scar 
97
. 
 
Early remodelling: Postinfarction remodelling has been divided in an early phase (within 72 
hours) and a late phase (beyond 72 hours). In the early phase, infarct expansion results from 
the degradation of the inter-myocyte collagen struts by serine proteases and the activation of 
MMP released from the neutrophils 
98
 and myofibroblasts 
44
. This phase of remodelling, due 
to infarct expansion, includes cardiomyocyte lengthening, infarct zone wall thinning, 
ventricular dilatation and elevation of diastolic and systolic wall stresses. The initial 
compensatory responses are invoked to maintain stroke volume (SV) after loss of contractile 
tissue in which the non-infarcted remote myocardium is involved 
99
. Infarct expansion causes 
deformation of the border and remote myocardium which augments shortening. Perturbations 
in circulatory hemodynamics stimulate the sympathetic adrenergic system, which triggers 
catecholamine synthesis by the adrenals and spillover from sympathetic nerve terminals, and 
stimulates the renin-angiotensin-aldosterone system (RAAS) 
97
. 
 
Late remodelling and hypertrophy: Research of global LV chamber volumes and muscle 
mass proves that early remodelling may continue progressively. The late remodelling 
involves myocyte hypertrophy as well as alterations of ventricular geometry and architecture. 
The LV becomes less elliptical and more spherical, and ECM forms a collagen scar to 
stabilize the distending forces and to prevent further deformation 
94, 97
. 
 
Cardiac hypertrophy is an adaptive response during late remodelling that offsets the 
enhanced load, progressively decreases dilatation and stabilizes contractile ability 
95
. Cardiac 
hypertrophy stimulates and regulates a diversity of transcriptional factors, enzymes and 
growth factors including natriuretic peptides, angiotensin-converting enzyme, and 
endothelin-1 
100-102
. Myocyte hypertrophy is triggered by neurohormonal activation, 
myocardial stretching, activation of local tissue RAAS, and paracrine/autocrine factors. 
Hypotension after MI triggers the sympathetic adrenergic system, which actives the RAAS 
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and stimulates the secretion of natriuretic peptides. Increasing secretion of norepinephrine, 
released from the sympathetic neurons, regulates myocyte hypertrophy directly and indirectly. 
Norepinephrine may activate α1 adrenoreceptors and causes myocyte hypertrophy through a 
Gαq-dependent signalling pathway. In addition, the stimulation of β1 adrenoreceptors in the 
juxtaglomerular apparatus, which is located in the kidney and regulates blood volume and 
pressure, induces renin release. Thereby, the production of angiotensin (Ang) II is increased 
103
. Furthermore, endothelin-1, another stimulus for myocyte hypertrophy, augments the 
release through stimulation of Ang II and norepinephrine. Serine proteases stimulate the local 
RAAS in the noninfarcted cardiac tissue, resulting in an increased expression of 
angiotensinogen. Renin then catalyzes the conversion of angiotensinogen to the decapeptide 
angiotensin1, which is subsequently hydrolyzed by angiotensin-converting enzyme to form 
Ang II 
104, 105
. These changes enhance local Ang II production, which is responsible for 
hypertrophy in noninfarcted myocardium 
97
 (Figure 4).  
Figure 4: Diagrammatic representation of the numerous factors involved in the 
pathophysiology of ventricular remodelling. RAAS, renin-angiotensin-aldosterone system; 
CO, cardiac output; SVR, systemic vascular resistance; and AII, angiotensin II 
97
. 
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Mechanical stretch is another way to induce hypertrophy in cardiomyocytes. Stretch induced 
hypertrophy mimics hemodynamic load-induced hypertrophy 
104, 106
. Mechanical stretch 
results in the secretion of Ang II from cytoplasmic granules of cardiomyocytes. It has been 
demonstrated that Ang II binding to its angiotensin type1 receptor induces hypertrophy and 
apoptosis of cardiomyocytes 
107
. Fortuno et al. 
108
 pointed out that apoptotic signals have the 
potential to produce an enlargement of cardiomyocytes. Subsequently, growth signals 
produce a contradictory genetic demand and trigger the apoptotic response when they persist 
chronically in terminally differentiated cells 
109, 110
. A molecular explanation for this double 
response may be the persistence of growth stimuli driving hypertrophied cardiomyocytes to 
lose intracellular survival signals that normally suppress the development of the apoptotic 
process 
111
. Hence, late remodelling is accompanied by hypertrophy and apoptosis of 
cardiomyocytes, defective vascular development, and fibrosis. Finally, this phenomenon is 
followed by transition to cardiac failure and progressive contractile dysfunction 
108, 112
. 
 
1.2      Approaches in regenerative medicine 
1.2.1    Angiogenic gene therapy and methods of gene delivery 
1.2.1.1   Mechanism of angiogenesis 
Normal tissue formation depends on adequate supply of oxygen and nutrition through blood 
vessels. In embryos, blood vessels are formed through two distinct pathways, vasculogenesis 
93
 and angiogenesis. Vasculogenesis takes place during embryonic development and leads to 
the formation of a primary vascular plexus. The term angiogenesis is used to describe the 
growth and remodelling process which then transforms the primitive capillary network into a 
complex network. This consists of an enlargement of venules, which sprout from pillars of 
peri-endothelial cells or from trans-endothelial cell bridges whose mother vessel split in turn 
into individual capillaries 
93
. In adults, angiogenesis plays an essential role for repair and 
regeneration of tissues for example during wounding healing 
113
. Bauters ’s group and 
Takeshita’s group have proven that a large number of factors such as VEGF, granulocyte-
monocyte colony-stimulating factor, bFGF and insulin-like growth factor (IGF)-1 are 
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essential for  development and differentiation of the vascular system 
114, 115
. Especially VEGF 
is thought to play a key role in de novo angiogenesis and wound healing. 
 
All members of the VEGF family activate cellular responses by binding to tyrosine kinase 
receptors (VEGFRs) on the cell surface, causing them to dimerize and to become activated 
by phosphorylation. Three specific receptor tyrosine kinases have been identified for VEGF, 
namely, VEGFR1, VEGFR2, and VEGFR3. A large number of studies 
116, 117
 have proven 
that cellular VEGF signalling is mainly mediated via VEGFR2. After VEGF binding to 
VEGFR2, endothelial cells may express endothelial nitric oxide synthase 
118
, produce nitric 
oxide 
117
, mobilize Ca
2+ 119
, migrate, and proliferate 
120
. VEGF inhibits endothelial cell 
apoptosis by activating a phophatidylinositol 3-kinase (PI3K)-dependent anti-apoptosis 
kinase pathway. Besides triggering the anti-apoptotic signalling pathway of endothelial cells, 
VEGF may promote the formation of new vessels and help maintain their integrity. Thereby, 
VEGF may mediate DNA synthesis and endothelial cell proliferation via VEGFR2. 
Furthermore, VEGF strongly induces the activity of the intracellular mitogen-activated 
protein kinase (MAPK). The activation of this pathway plays an important role in the 
stimulation of endothelial cell proliferation 
116, 121
. Also, VEGF may stimulate 
phosphoinositide  phospholipase C (PLC) -γ tyrosine phosphorylation and then trigger 
protein kinase C and Ca
2+
 mobilization. Studies indicated that the activation of protein kinase 
C plays a vital role in endothelial cell proliferation 
122-125
. It has been proven that VEGF 
stimulates endothelial production of nitric oxide and prostacyclin 
126-130
. Normally, nitric 
oxide production is stimulated by VEGF via the activation of a constitutive endothelial nitric 
oxide synthase isoform, in part through VEGF-induced Ca
2+ 
mobilization. It is well known 
that nitric oxide is crucial for vasodilation, however, it also has some vascular protective 
effects, such as anti-platelet, anti-thrombotic effects, as well as inhibition of leukocyte 
adhesion 
131
. Concerning the functions of promoting angiogenesis and protecting vascellum, 
VEGF may have the potential for promoting therapeutic angiogenesis and consequently 
enhancing heart function 
132
  (Figure 5). 
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Figure 5: Signaling pathways activated by VEGF: VEGF regulates several endothelial cell 
functions, including differentiation, proliferation, permeability, and the production of 
vasoactive molecules. Upon ligand binding, the receptor is phosphorylated, allowing the 
receptor to stimulate a range of signaling molecules, such as the SHP-1 and SHP-2, and PI3K. 
VEGF receptor activation can induce activation of the MAPK cascade leading to gene 
expression and cell proliferation, stimulation of PI3K leading to PKB activation and cell 
survival, stimulation of PLC-γ leading to cell proliferation, vasopermeability, and 
angiogenesis. Src homology region 2 domain-containing phosphatase (SHP); protein kinase 
B (PKB). (Picture is from www.sigmaaldrich.com/life-science/cell-biology/learning-center.) 
 
1.2.1.2 Clinical trials investigating therapeutic angiogenesis  
Although conventional mechanical revascularisation by percutaneous coronary 
intervention (PCI) and coronary artery bypass graft (CABG) have reduced the morbidity 
and mortality significantly, some patients are unsuitable for these surgical techniques and a 
substantial proportion of PCI and CABG patients experience incomplete revascularization. 
Therefore, there is an important clinical need for additional treatment options of ischemic 
heart disease. The aim of therapeutic angiogenesis is the use of angiogenic factors to induce 
the formation of a collateral blood supply, suitable to transport sufficient amounts of oxygen 
and nutrients, and to thereby reduce and repair myocardial damage. In animal studies, several 
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families of proteins have been shown to have angiogenic potential in ischemic heart tissue 
133, 
134
. However, in pre-clinical trials, VEGF had the highest potential to induce angiogenesis. 
To date, there are more than 25 phase II and phase III clinical trials including 2300 patients, 
assessing the functions of recombinant angiogenic growth factors or therapeutic genes 
encoding for these growth factors including VEGF as well as fibroblast growth factors in 
patients with ischemic heart disease 
135, 136
. 
 
VEGF gene therapy: Gene therapy is one optional way of delivering therapeutic cytokines 
to achieve a more steady biological effect. Preclinical and clinical studies of VEGF gene 
delivery encoded in plasmids or Ad proved an impressive enhancement of cardiac function in 
diverse animal models 
137, 138
. The methods employed in clinical trials to deliver genes to 
cardiac tissue have included direct intracoronary infusion and direct intramyocardial injection 
during bypass surgery. Plasmids encoding the VEGF gene have been used as naked plasmid 
DNA or in transfection formulations such as a liposome plasmid DNA complex. The first 
group to perform cardiac VEGF gene therapy, Orlic’s group 139, investigated VEGF A 
encoded in plasmid DNA for patients with severe coronary artery disease (CAD). Their 
results demonstrated that the clinical use of plasmids is therapeutically safe and shows 
promising signs of clinical benefit. However, in two randomised, double-blind, placebo-
controlled trials of VEGF therapy, no significant difference between the VEGF treated group 
and the placebo group were detected concerning the primary end point, amelioration of 
myocardial perfusion. Meanwhile, most phase II/III trials of therapeutic angiogenesis in CAD 
using plasmid vectors have negative results. Even though plasmid vectors have many 
advantages such as being simple to manufacture and comparatively safe, the main drawback 
is the low transfection efficacy of pure plasmid vectors.  
 
Although mainly secreted diffusible proteins such as VEGF have been used for therapeutic 
angiogenesis, which could theoretically achieve a widespread effect even if relatively few 
cells are transfected, it has been argued that viral vectors which can transduce a much larger 
proportion of cells in the target tissue are able to achieve a sufficient expression level for a 
therapeutic effect 
135, 136
. Even though several types of viral vectors are available including 
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vectors of retroviral, lentiviral and adenoviral type, so far, adenoviruses have been the best 
candidates for cardiovascular disease therapy, because they display a high transduction 
efficacy in many proliferating and non-proliferating cell types. Although concern has been 
raised about the safety of adenoviruses, their genomes have not been found to integrate into 
host genome at high frequency, and episomal viral genomes are rapidly lost from dividing 
cells. Furthermore, many adenoviral serotypes are only mildly pathological. Intramyocardial 
AdVEGF injection via thoracotomy was proven to be safe and well tolerated by 21 patients in a 
phase I study 
140
. In the Kuopio angiogenesis phase II trial, 103 patients with untreated 
angina were randomised to receive either AdVEGF or placebo. Vectors were infused by an 
infusion-perfusion catheter during the stent placement. A significant enhancement of heart 
perfusion was shown in the treatment group compared to the placebo 
141
.  
 
1.2.1.3 Delivery techniques in experimental and clinical use 
Systemic intravenous injection and magnetically guided intravenous injection: In 
experimental and clinical practice, many therapies are applied by venous delivery. In general, 
systemic injection is a cornerstone of medical therapy. However, lack of targeting specificity 
leads to the presence of therapeutical agents in organs such as liver, lungs, spleen, and kidney 
and thus limits systemic injection due to the resulting poor cardiac uptake. Therefore, in the 
context of intravenous gene therapy, increasing cardiac specificity, for instance by using 
cardiac specific promoters and viral vectors that lead to relative cardiac tropism, is a possible 
solution for this problem. 
 
Magnetic nanoparticles (MNPs) based transfection was first established in the 1970s for 
magnetically targeted drug delivery. Cathyrn Mah and her colleagues 
142
 were the first to 
successfully use adeno-associated viral vectors (AAV) linked to magnetic microspheres via 
heparin for in vitro and in vivo transduction. Since this initial study, the term 
‘magnetofection’ has been established. This technique is based on the binding of genetic 
material such as a viral vector to magnetic nano or micro particles. For in vitro transfection, 
the MNPs/genetic construct complex is incubated with cultured cells in a cell culture plate 
and a magnetic field gradient is produced by magnets positioned beneath the plate. The 
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external magnetic field gradient increases sedimentation of the complex as well as speed and 
efficacy of transfection. In vivo, a magnetic field focused over the target site has the potential 
not only to enhance transfection efficacy, but also to target therapeutic genes towards a 
specific organ or site of the body 
142
.  
 
The physical principles of magnetofection are based on the attractive force exerted on MNPs 
by a magnetic field source according to the Equation 1. 
 
 
 
Equation 1: Fmag is the force on the magnetic particle, χ2 is the volume magnetic 
susceptibility of the magnetic particle, χ1 is the volume magnetic susceptibility of the 
surrounding medium, µo is the magnetic permeability of free space, V is the particle volume, 
B is the magnetic flux density in Tesla (T),   B is the field gradient and can be reduced to 
δB/δx, δB/δy, δB/δz 143. 
 
From Equation 1 I can deduce that high gradient, rare-earth magnets are highly preferable 
for magnetofection. Meanwhile, the magnetic field must have a high gradient in order to 
generate an appreciable force on the magnetic particles. In the presence of a homogeneous 
field, the particle will not be subjected to any force. Equation 1 also indicates that several 
other parameters can influence the force on the magnetic particles including particle number, 
magnetic field strength and the magnetic properties of the particles.  
 
The technique of MNB-based gene therapy is widely applied and a series of studies have 
proven that in vitro MNB based infection increased sedimentation of the complex as well as 
speed and efficiency of transfection. In vivo, the therapeutic gene may be specifically 
expressed in a target site or organ of the body and transduction efficiency can be enhanced by 
additional guiding by a magnetic field. Pandori and colleagues 
144
 utilized streptavidin and its 
ligand biotin to associate Ad to silica beads which resulted in higher infection efficiency for a 
variety of cell lines and an improved localization by magnetic force. Moreover, Hofmann et 
al. 
145
 used charge to couple MNPs to lentiviral vectors (LVs) and applied MNPs to 
combine cell transduction and positioning in the vascular system. Additionally, in vivo 
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MNPs/LVs biodistribution was proven to be significantly changed by external magnetic field 
intervention in a murine model 
145
.  
 
Generally, MNPs/therapeutic gene complexes can be injected intravenously and external 
magnets are used to guide and attract complexes as they flow through the blood stream.  
Once captured by the magnetic field, the complexes will be held within the target area and 
taken up by the tissue. Furthermore, therapeutic genes may be released and expressed in the 
targeted zone 
146, 147
.  
 
1.2.2 Tissue engineering combined stem cells for cardiac regeneration 
Heart disease is the leading cause of death worldwide, due to the fact, among other aspects, 
that the heart is one of the least regenerative organs in the human body. Stem cell therapy has 
been proposed as a promising strategy for cardiac repair following myocardial damage 
because of the plasticity of stem cells. Direct myocardial cellular therapy and/or cytokine 
mobilization are undergoing investigation for the treatment of MI 
148
. Evidence suggests that 
cell therapy employing bone marrow-derived or circulating progenitor cells for MI can 
improve cardiac function 
149-151
, no matter if the differentiation of the stem cells to myocyte-
like cells occurs 
139, 152, 153, 154
. However, the use of stem cells for myocardial repair remains 
controversial 
155, 156
. This suggests that the rate and type of cellular regeneration in the injured 
myocardium may rely not only on the ability of stem cells to transdifferentiate into myocytes 
or endothelial cells, but also on surrounding factors that play essential roles in creating 
conditions conductive to stem cell-mediated cardiac repair.  
 
C-kit is a receptor tyrosine kinase 
157
, which constitutes a type III protein tyrosine kinase 
superfamily with the receptors for platelet-derived growth factor (PDGF) 
158
, colony-
stimulating factor 1 and flt-3 ligand 
159, 160
. Upon ligand binding, the tyrosine kinase subunit 
of c-kit is enabled to bind src homology domain-containing proteins, including proteins of 
the p21 MAPK pathway and the p85 subunit of PI3K. Subsequently, those proteins are 
activated and trigger signalling cascades that cause various cellular responses including 
migration, survival, and proliferation 
161
. In addition, it has been proven that haematopoietic 
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derived c-kit+ stem cells have the function to improve cardiac performance after MI 
152, 153, 
162
. Fazel et al. 
162
 showed that coronary ligation leads to a significant recruitment of c-kit+ 
cells from peripheral blood. After MI, c-kit+ cells could be found in the injured heart tissue 
that is subtended after the ligated coronary artery. However, c-kit+ stem cell therapy for 
myocardial repair is thought to be partly limited by the number of stem cells that bear 
insufficient potential for migration, survival, and, differentiation into the cardiac cell types. 
 
Tissue engineering materials such as bio-artificial tissue have a great potential for 
regenerating heart function, which is, nevertheless, associated with significant limitations. 
The bio-artificial tissue needs to be robust enough to endure high ventricular wall stress 
during the heartbeat. The heart constitutes a complex helical structure with significant local 
asymmetry and anisotrophy 
163
. Different parts of the heart display a distinct mechanical 
performance and microstructure. The contractions of particular elements in all areas of the 
ventricle have to be coordinated to guarantee maximal hemodynamic output 
164
. The majority 
of previously used biodegradable rigid materials which were designed for implantation into 
the injured ventricular wall cannot achieve this goal. 
 
Matrigel is a basement membrane extract containing collagen that is secreted by a mouse 
sarcoma cell line 
165
. Additionally, matrigel contains a large number of growth factors and 
cytokines such as IGF-1, PDGF, bFGF, and VEGF 
166
. It is well known that IGF-1 promotes 
cytoprotection 
167
 and PDGF has been shown to prevent cardiac cell apoptosis post-MI 
168
. 
Meanwhile, bFGF and VEGF as pro-angiogenic factors may promote neovascularization, 
increase capillary and arteriole densities. Therefore, these factors may preserve cardiac cell 
survival after MI by promoting the restoration of blood flow to the ischemic cardiac tissue 
169-173
.  In addition, matrigel constitutes a functional platform to reduce the rate of diffusion 
and prolong the half-life of the therapeutic factors which it contains 
174
.   
 
After MI, the mobilization of c-kit+ stem/progenitor cells into the peripheral blood and the 
significant recruitment of c-kit+ stem cells to the infarcted heart are associated with a short 
term, temporally, and spatially distributed up-regulation of SCF. Matrigel could reinforce 
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stem cell homing by the release of various therapeutic molecules promoting anti-apoptosis 
and pro-angiogenesis. Moreover, matrigel may provide an appropriate environment by 
secreting the therapeutic molecules to support c-kit+ cell survival and proliferation via the 
growth factors mentioned above 
164, 175-179
. 
 
1.2.3 Goal of the thesis 
Based on these studies, I hypothesized that in a rat MI model, intravenous MNB based 
delivery of therapeutic genes/VEGF complexes could be targeted towards the ischemic area 
of the heart via externally applied magnetic force. Thereby, targeted VEGF expression in the 
heart may promote neovascularization and improve cardiac function. Overall, MNB based 
VEGF delivery and therapy may be a useful, non-invasive therapeutic strategy with good 
potential for treatment of MI. 
 
On the other hand, the technique of local matrigel injection may provide several advantages 
for MI therapy. Firstly, matrigel delivery by catheterization has the benefit of minimal 
invasion. Secondly, Matrigel, as bio-artifical ECM, may support a series of growth factors in 
enhancing the recruitment of c-kit+ cells and in regulating their survival and proliferation. 
Last but not the least, matrigel may provide three-dimensional support to reduce negative 
remodeling processes of the infarcted area. Therefore, matrigel combined with c-kit+ stem 
cell therapy can be expected to become a promising strategy to treat MI. 
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2    Material & methods
1
 
2.1  HUVECs isolation and culture 
Human umbilical vein endothelial cells (HUVECs) were isolated from umbilical cord, and 
expanded. Firstly, the fresh umbilical cord was placed in a 25 cm dish. Then it was washed 
with phosphate-buffered solution (PBS) to clear the blood away. The cord was checked for 
clamp damage, and the damage part was removed. Using PBS, the vein of the cord was 
washed until it ran clear.  Then umbilical cords were washed with 0.2-mm-filtered cord buffer 
(140 mM NaCl, 4 mM KCl, 2 mM MgCl2, 11 mM glucose, 10 mM HEPES [pH 7.4]) and 
reperfused with 0.2-mm-filtered cord buffer containing 1% bovine serum albumin (Sigma 
Aldrich, St. Louis, USA) and 0.05% Clostridium histolyticum collagenase (Sigma Aldrich, St. 
Louis, USA). The cord was clamped and incubated at 37°C for exactly 13 minutes. Every 3 
minutes, the cord was gently flushed with the collagenase solution back and forth. After 
incubation, the collagenase solution was removed and transferred to a 50ml tube. The vein 
was flushed with Roswell park memorial institute medium (RPMI) 1640 (Lonza, Basel, 
Switzerland), collecting the flow-through in a 50ml tube. The RPMI 1640 containing the 
HUVECs was subsequently pelleted by centrifugation for 6 minutes at 1000 revolution(s) 
per minute (rpm). The supernatant was aspired carefully and the cell pellets were re-
suspended in 1ml RPMI 1640. Finally, 10 µl aliquots were taken for mononuclear cell count. 
Cells were then plated in 60 mm plastic culture dishes at a cell density of 2.5 × 10
6
 cells/cm
2
 
in RPMI 1640 containing 20% fetal calf serum (PAN Biotech, Aidenbach, Germany), 5% 
endothelial mitogen (Biomedical Technologies, Stoughton, USA), 100 μg/ml of streptomycin 
(PAA, Pasching, Germany) at 100 units/ml of penicillin (PAA, Pasching, Germany), 14 mM 
HEPES (pH 7.4) and 2 mM L-glutamine and the cells were grown at 37°C and 5% CO2 
atmosphere, and the medium was changed every 2 days. After 80% confluence was achieved, 
adherent cells were defined as passage 0. Cells were harvested using trypsin and 
subsequently replated in endothelial medium (Lonza, Basel, Switzerland) for continued 
                                                 
1
 Parts material & methods are described in [173], [180].  Please see the list of own publications. In the following, 
the text printed in italics is a citation of the text from these papers. 
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passaging. Medium was changed three times per week. After HUVECs became confluent to 
90%, cells were kept in liquid nitrogen for long-term storage. After third passage, cells can 
be used for subsequent in vitro experiments. 
 
2.2 MSCs isolation and culture 
Rat mesenchymal stem cells (MSCs) were isolated from rat bone marrow, and expanded. 
Firstly, the femur and tibia of rat hind legs were harvested and cut open. A 23-gauge needle 
was inserted into the bone to flush the bone marrow out using 30 ml Dulbecco's modified 
eagle medium (DMEM) (PAN Biotech, Aidenbach, Germany) with 10% fetal bovine serum 
(PAN Biotech, Aidenbach, Germany). The medium with the bone marrow was collected in a 
50 ml tube. For density gradient centrifugation, a fresh 50 ml tube with 15 ml Ficoll (Sigma 
Aldrich, St. Louis, USA) was prepared and 30 ml DMEM including the rat bone marrow 
cells was overlayered onto to the Ficoll carefully. The tube was centrifuged at 2000 rpm for 
30 minutes at 20°C. The mesenchymal stem cell-enriched mononuclear cell population was 
then aspirated with a Pasteur pipette (Sigma Aldrich, St. Louis, USA) (approximately 1 ml) 
and washed with PBS by further centrifugation at 1600 rpm for 10 minutes at 20°C. The 
pellets were re-suspended in 10 ml of DMEM. 10 µl aliquots were taken for mononuclear 
cell count. Mononuclear cells were then plated in 100 mm plastic culture dishes at a cell 
density of 1 × 10
7
/cm
2
. Cells were grown at 37°C and 5% CO2 atmosphere, and the DMEM 
was changed every 2 days. After 80% confluence was achieved, adherent cells were defined 
as passage 0. Cells were harvested using trypsin and subsequently replated for continued 
passage. Medium was changed once every two days. After MSCs became 80% confluent, 
cells were harvested by trypsinization and subsequently kept in liquid nitrogen for long-term 
storage. After third passage, cells have been used for in vitro experiments. 
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2.3 Viral vector amplification and purification 
Ad5. cytomegalovirus (Vector Biolabs, Philadelphia, USA) is derived from adenovirus 
serotype 5 with the deletion of the viral E1 and E3 genes. These Ad could carry LacZ, green 
fluorescent protein (GFP), luciferase and human VEGF gene separately under the control of 
the human cytomegalovirus immediate-early promoter with a polyadenylation site. These 
viral vectors were produced by using the 293A cell line (Invitrogen, Carlsbad, USA), a 
subline of 293 cells (human embryonal kidney cells transformed by sheared adenovirus 
serotype 5 genome), and purified by adenovirus purification kit (Clontech, Shiga, Japan). 
Firstly, low passage 293a cells were seeded on several 15 cm dishes with a density of 1.5 × 
10
7
 cells/dish. Subsequently, the adenoviral stock solution was used to infect the 293a cells. 
The infected cells were incubated at 37°C and a humidified atmosphere containing 5% CO2 
for 3-5 days until the cytopathic effect was complete. The pellets of 293a cells were 
centrifuged at 1500 rpm for 10 minutes. The supernatant was discarded. The cell pellets were 
re-suspended in 5 ml of fresh DMEM. Three consecutive freeze-thaw cycles were performed 
to lyse the cells. After the final thawing, the lysate was centrifuged at 3000 rpm for 5 minutes. 
The supernatant was collected in a sterile centrifuge tube and the pellets were discarded. 
Then 5 µl nuclease (Clontech, Shiga, Japan) was added to the supernatant and the mixture 
was incubated for 30 minutes at 37 °C. After that, 5 ml dilution buffer were added to the tube 
and the lysate was clarified by filtering it through a 0.45 µm filter (Millipore, Billerica, USA). 
The lysate was passed through an adeno-purification filter (Clontech, Shiga, Japan) to load 
the Ad onto the purification filter. For the final step, 3 ml 1 × elution buffer (Clontech, Shiga, 
Japan) was passed through the adeno-purification filter to elute the Ad. The original 
preparation of Ad was aliquoted and stored frozen at -80°C. 
 
2.4 MNBs/Ad complexes formation  
Firstly, an appropriate amount of 100 nm average effective diameter Streptavidin 
MagneSphere® MNBs (Promega, Fitchburg, USA) were washed two times using PBS and 
re-suspended in PBS. For the next step, Sulfo-NHS-LC-biotin (Pierce Chemical, Rockford, 
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USA) was used as the biotinylation reagent. 5 mg Sulfo-NHS-LC-biotin was diluted in 1 ml 
PBS to a final concentration of 5 mg/ml. 50 µl of diluted Sulfo-NHS-LC biotin solution was 
mixed with 0.5 × 10
 10
 plague-forming unit (pfu) Ad in 450 μl PBS (pH 7.6) to a final 
concentration of 500 ng/ml. The mixtures were placed on ice, in the dark, for 2 hours, and 
subquently, 90 mM glycine in PBS was added to each reaction mixture to absorb excess 
sulfo-NHS-LC-biotin. Next, a desalting column (Promega, Fitchburg, USA) was used for the 
removal of the remaining free biotinylation reagent. Finally, MNBs were added to 
biotinylated Ad and the complexes were provided by vortexing for 30 seconds and followed 
by incubation at room temperature for 30 minutes. The biotinylated Ad were coupled to 
MNBs via the Streptavidin linker. The original preparation of MNBs/Ad complexes was 
stable in aqueous solution and was stored at -80°C. 
 
2.5 HUVECs network formation to evaluate VEGF function 
HUVECs were seeded 2 × 10
4
 per well of a 6 well plate and incubated overnight at 37°C and 
5 % CO2. Before transduction, AdhVEGF were added to 250 µl endothelial medium (without 
VEGF). After incubation for 5 minutes, medium including AdhVEGF was added to HUVECs. 
Then HUVECs were incubated with AdhVEGF for 24 hours (untransduced HUVECs were used 
as the control group). Before network formation experiments, 200 µl matrigel was pipetted 
per well of a 12 well plate with pre-cooled tips. The plate with matrigel was incubated at 
37°C for 30 minutes. Subsequently, transduced HUVECs were carefully seeded on the 
matrigel-coated plate and incubated overnight. Computer-assisted Zeiss microscopy (Carl 
Zeiss, Jena, Germany) was used to analyze network formation. 
 
2.6 In vitro transduction 
In vitro transduction efficiency of Ad or MNBs/Ad encoded luciferase (Adluc) complexes 
was evaluated by the luciferase reporter gene in HUVECs. The HUVECs were maintained in 
endothelial medium with 100 μg/ml of streptomycin at 100 units/ml of penicillin, at 37°C, in 
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a humidified 5% CO2 incubator. HUVECs were seeded in 48-well plates at a density of 5 × 
10
4
 cells per well 24 hours prior to the transduction. Before the transduction, the cells were 
allowed to achieve 50%-60% confluence. Throughout the transduction, the culture medium 
was aspirated and replaced with 0.5 ml fresh medium, meanwhile MNBs/Adluc complexes 
were added to the fresh medium. The cells receiving Adluc alone were taken as control. Cell 
culture dishes were kept with a magnet placed underneath for 30 minutes. The size of the 
cylindrical sintered neodymium-iron-boron magnet (NeoDelta; remanence Br: 1080–1120 
mT) (IBS, Berlin, Germany) was 6 × 5 mm (diameter × height). Cells were incubated with 
complexes for 24 hours at 37°C, in a in a humidified 5% CO2 incubator. Following the 
incubation, the cells were washed with PBS and lysed with 100 μl of cell lysis buffer 
(Promega, Fitchburg, USA). Luciferase activity in cell extracts was measured by using the 
luciferase reporter assay kit (Promega, Fitchburg, USA) on a 96-well microplate 
luminometer (EG&G Berthold, Stuttgart, Germany). The relative light units were normalized 
against protein concentration. Protein concentration was measured by a microplate reader 
using the bicinchoninic acid protein assay kit (Pierce Chemical, Rockford, USA).  
 
2.7 MTT cytotoxicity 
Cytotoxicity of MNBs/Ad was evaluated by performing [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide] (MTT) (Sigma Aldrich, St. Louis, USA) assay. HUVECs 
(1 × 10
4
 cells/well) were seeded into the 96-well plates. The MNBs/Adluc complexes were 
added 24 hours after seeding. The cells were incubated in 200 µl medium containing 
different doses of MNBs and Ad. After 40 hours of incubation at 37°C, in a humidified 5% 
CO2 incubator, the metabolic activity of the HUVECs was analyzed. Firstly, 15 μl of 5 
mg/ml MTT stock solution in 1 × PBS was added into each well. After 4 hours of incubation 
at 37°C, in a humidified 5% CO2 incubator, the medium was removed and 100 µl of 
extraction buffer (20 µg purple crystals (Sigma Aldrich, St. Louis, USA) were dissolved in 
100 μl dimethylsulfoxide (Sigma Aldrich, St. Louis, USA) was added to each well and the 
plates were incubated for 2 hours in the dark at 37°C, in a humidified 5% CO2 incubator. 
Finally absorbance was measured at a wavelength of 550 nm and a reference wavelength of 
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655 nm using a microplate reader (Bio-Rad, Hercules, USA). The results were expressed as 
the percentage of viability relative to the control cells, which were cultured without 
complexes treatment. Cell viability was calculated using the Equation 2.  
Equation 2: Cell Viability (%) = (OD550-OD655) samples / (OD550-OD655) control × 
100%. 
 
2.8 Characterization of MNBs/Ad complexes  
The solution containing the Ad complexes was diluted with PBS to the final amount of Ad of 
8 × 10
 7
 pfu. Subsequently, different doses of MNBs were added to prepare complexes with 
different MNB/Ad ratios. MNBs/Ad complex size was measured with ZetaPALS analyzer 
(Brookhaven Instruments, Älvsjö, Sweden) by dynamic light scattering at 25°C.  
 
2.9 Magnetic field guided in vitro transduction 
HUVECs were incubated for 24 hours with MNBs/Ad encoded lacZ (AdlacZ) complexes by 
the reporter gene LacZ in the presence of three cylindrical magnets (each 6 mm in diameter) 
affixed to the bottom of a 10 cm culture dish. Three cylindrical magnets were evenly attached 
to the bottom of the dish to form a three-point magnetic field pattern prior to the application 
of MNBs/AdlacZ complexes. The positions of three magnets were adjusted to exclude the 
possibility of passive accumulation of complexes in the center or along the peripheral edge of 
the dish. The dish was subjected to gentle agitation at room temperature for 30 minutes and 
further cultured for 48 hours without the magnets. MSCs were transduced by AdlacZ 
complexes as described above. MSCs were incubated for 24 hours with AdlacZ complexes by 
the reporter gene LacZ in the presence of one rectangular magnet (20 × 10 × 5 mm (length × 
width × height)) affixed to the bottom of one well of a 6 well dish. β-gal staining kit 
(Invitrogen, Carlsbad, USA) was used to evaluate LacZ gene expression. MSCs were also 
transduced by MNBs/Ad encoded GFP (AdGFP) complexes as described above. MSCs were 
incubated for 24 hours with MNBs/AdGFP in the presence of one cylindrical magnet (6 mm in 
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diameter) affixed to the bottom of one well of a 24 well dish. Finally, gene expression was 
observed using a Leica SP2 Confocal Microscope (Leica, Solms, Germany).  
 
2.10 Experimental design of MNBs/hVEGF for cardiac regeneration 
For this study, Lewis rats (male, 250 ± 5 g), which were purchased from Charles River 
Laboratories (Sulzfeld, Germany) were used. The federal animal care committee of the 
Landesamt für Landwirtschaft, Lebensmittelsicherheit und Fischerei (Mecklenburg-
Vorpommern, Germany) approved the study protocol (approval number M-V/TSD/7221.3-
1.1-080/11). All animal procedures were performed in accordance with requirements of the 
“Animal Care and Use Committee” of the Medical Faculty, University of Rostock. During 
the surgery, the body temperature of the rat was maintained at 37.5 degree ± 0.5 using a 
heating table. In the first postoperative days, rats were offered NovaMin sulfone (Metamizol, 
Frankfurt, Germany) (10 drops/300 ml water) to mitigate pain the drinking water was 
replaced daily. Furthermore, the animals` conditions such as activity, behaviour, lethargy, 
lack of appetite, and hair texture were assessed each day. The rats were euthanized, when 
they exhibited significant impairments of their conditions. 
 
Rats were randomly assigned to 7 groups as follows: MI-Magnet
+
 MNBs/AdhVEGF  n = 18;
 
MI-Magnet
-
MNBs/AdhVEGF,  n = 18; MI-MNBs, n = 18; MI-Saline, n = 18; sham-operation, 
n = 13; MI-Magnet
+
MNBs/AdGFP, n = 8; and MI-Magnet
-
MNBs/AdGFP, n = 8. Usually, three 
methods can be used to induce MI: The surgical ligation model, the cryo-injury model, or the 
pharmacologically-induced model. In this experiment, the surgical ligation method was used 
to induce MI. The surgical procedure consists of three steps. Firstly, the rat was anesthetized 
intraperitoneally with Ketamine (60 mg/kg body weight)/Xylazin (10 mg/kg body weight) 
(Sigma Aldrich, St. Louis, USA) and its heart was exposed following a left thoracotomy 
between the third and fourth intercostal space. Secondly, the left anterior descending 
coronary artery (LAD) was ligated by a 6-0 surgical suture permanently (Figure 6 A). 
After the anterior wall of LV blanched, the procedure was considered successful. Finally, the 
chest was closed by a 4-0 surgical suture. This ligation technique of LAD is simply, well-
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reproducible, and may cause permanent ischemia to the cardiac tissue of the LV. After the 
surgery, a 6 × 2 × 2 mm cylindrical NdFeB magnet (Br: ≈ 1000m Tesla) (IBS, Berlin, 
Germany) was placed in the chest of the rat closely adjacent to the blanched area of the 
heart, then the magnet was fixed between the third and the fourth rib of the rat by a 4-0 
suture (Figure 6 B). In the MI-Magnet
-
MNBs/AdhVEGF group, the operation procedure was 
identical except for magnet placement. The saline group underwent the identical surgery 
procedure of LAD ligation. A sham operation was performed on another group of rats by 
passing a suture around the LAD without ligation. 24 hours after infarction, Ad encoded 
hVEGF (1 × 10
10
 pfu/ml) or GFP (1 × 10
10
 pfu/ml) coupling to 500 μl MNBs, MNBs alone, 
or saline were injected into the rat body in a total volume of 1 ml through the tail vein. 
Animals from each groups (n = 4) were sacrificed 48 hours and 7 days after systemic 
administration and transgene expression was evaluated by immunohistochemical staining and 
Real-Time polymerase chain reaction (PCR) in different organs (kidney, heart, lung, liver, 
and, spleen). The remaining animals were used for histopathological analysis and heart 
functional evaluation (Figure 6 C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
A 
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Figure 6: Experimental design. (A-B) After LAD-ligation the rats received the magnet fixed 
onto the area of infarcted myocardium. (C) In vivo experimental design. (Figure 6B quoted 
from 
[173]
) 
 
2.11 FACS analysis for inflammatory response 
Analysis of peripheral blood was performed 7 days (n = 4, for each group) after MI. To 
examine the effects of Ad treatment on inflammation, rat mononuclear cells were isolated 
from peripheral blood. Firstly, 10 ml venous blood was harvested in a heparinized blood 
collection tube. The blood was then transferred into a 50 ml tube. Furthermore, one new 50 
ml tube with 10 ml Ficoll was prepared, and 10 ml peripheral blood was carefully 
overlayered onto the Ficoll. The tube was centrifuged at 2000 rpm for 30 minutes. The 
mononuclear cell population was then aspirated with a Pasteur pipette (approximately 1 ml) 
and washed in 20 ml PBS by further centrifugation at 1600 rpm for 10 minutes at 20°C. The 
pellets were re-suspended in 10 ml of PBS. Then the samples of mononuclear cells were 
stained for flow cytometry analysis. Cells were incubated with anti-rat CD8
+
T monoclonal 
antibody (Santa Cruz, Dallas, USA). Subsequently, donkey anti-rat Alexa-Fluor 488 
conjugated secondary antibody (Molecular probesTM, Carlsbad, USA) was applied to the 
C 
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samples. The number of CD8
+
T cells in the mononucelar cell fraction of peripheral blood 
was examined by fluorescence-activated cell sorting (FACS) (Calibur, New Jersey USA). 
 
2.12 Quantitative Real-Time PCR and immunohistochemical staining 
analysis for Ad distribution 
To investigate the Ad expression and distribution in vivo, mRNA levels of AdhVEGF were 
evaluated in different organs. Seven days after Ad injection, heart, liver, spleen, lung, and 
kidney from each group (n=4) were collected and snap-frozen in liquid nitrogen. Total RNA 
was isolated following the instructions of the TRIZOL
®
 Reagent (Invitrogen, Carlsbad, USA). 
Firstly, the tissue sample was placed in a tube and 1 ml of TRIZOL reagent was added to the 
tissue sample. After 5 minutes of incubation, 0.2 ml chloroform (Sigma Aldrich, St. Louis, 
USA) was added to the sample. The sample was shaken 2-3 times and centrifuged at 12000 
rpm, for 15 minutes. Throughout the centrifugation, the mixture was segregated into two 
phases: a lower red, phenol-chloroform phase and a colourless upper aqueous phase. As the 
RNA remains in the upper phase, this aqueous phase was transferred into a new tube without 
disturbing the interphase. Subsequently, 0.5 ml isopropanol (Sigma Aldrich, St. Louis, USA) 
was added to the aqueous phase and the sample was centrifuged at 12000 rpm, for 10 minutes. 
Following centrifugation, the supernatant was removed completely and the RNA pellet was 
washed with 75% ethanol (Sigma Aldrich, St. Louis, USA). Then the sample was centrifuged 
at 7500 rpm, for 5 minutes. Again, the supernatant was removed and the sample was air dried 
for 10 minutes. Finally, 1 μl of sample RNA was diluted with 39 µl of DEPC-treated water 
(Sigma Aldrich, St. Louis, USA) (1:40 dilution). 10 μl of the sample was used to determine 
sample concentration by OD 260 nm and 280 nm method. For quantitative Real-Time PCR, 
human VEGF primer (Applied Biosystems, Carlsbad, USA) was used. Amplification and 
detection were performed with the StepOnePlus™ Real-Time PCR System (Applied 
Biosystems, Carlsbad, USA) in TaqMan Universal Master Mix (Applied Biosystems, 
Carlsbad, USA) according to the instructions of the manufacturer (Applied Biosystems, 
Carlsbad, USA) and repeated at least three times using the following program: 1 cycle of 
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50°C for 2 minutes, 1 cycle of 95°C for 10 minutes, and 40 cycles of 95°C for 15 seconds and 
60°C for 1 minutes. cDNA extracts were tested in at least triplicate and negative controls 
were included in each assay. Cycle thresholds (CT) for single reaction were determined with 
StepOne™ Software 2.0 (Applied Biosystems, Carlsbad, USA) and the target genes were 
normalized against GAPDH (Equation 3: ΔCT = CT target - CT GAPDH ). Resulting ΔCT of 
triplicates was averaged and ΔΔCT were obtained using sham group as calibrator sample 
(Equation 4: ΔΔCT = ΔCT sample - ΔCT calibrator sample). In the current study, the 2
-ΔΔC 
method was 
employed to present changes in gene expression.  
 
2.13 Immunohistochemical staining analysis of hVEGF expression in 
the heart 
For immunohistochemical staining detection of hVEGF expression, frozen transverse tissue 
sections (8 µm thickness) of hearts from MI-Magnet
+
MNBs/AdhVEGF and MI-Magnet
-
MNBs/AdhVEGF groups (n = 4 for each group) were selected. The slides were allowed to dry 
for 20 minutes at room temperature. Then a boundary between each two samples on the same 
slide was drawn by DAKOCytomation pen (Dako Cytomation, Glostrup, Denmark). The 
tissue sections were fixed by covering with 1% paraformaldehyde (Sigma Aldrich, St. Louis, 
USA) for 10 minutes. After fixation, the samples were washed twice with PBS. One drop of 
protein block solution (Dako Cytomation, Glostrup, Denmark) was added to each slide to 
cover the tissue section. Then the tissue sections were incubated with rabbit anti-hVEGF 
antibody (R&D, Minneapolis, USA) at 4°C overnight. Subsequently, the sections were 
incubated with donkey anti-rabbit Alexa-Fluor 405 (Molecular probesTM, Carlsbad, USA) 
conjugated secondary antibody. Nuclei were counterstained with TO-PRO3 (Molecular 
probesTM, Carlsbad, USA). Finally, the slides were washed 5 times by immersing in PBS for 
5 minutes at room temperature and then coverslips were used to cover the tissues and nail 
polish was used to seal the border. Labelled sections were observed using a Leica SP2 
Confocal Microscope.  
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Moreover, in order to identify cell types infected by AdhVEGF in the infarcted heart, 
immunohistochemical staining was performed. Firstly, the hVEGF expression in endothelium 
was evaluated. After slides were stained with hVEGF, the tissue sections were incubated 
with polyclonal goat anti-CD31 primary antibody (Santa Cruz, Dallas, USA) at 4°C 
overnight. Subsequently, the sections were incubated with anti-goat Alexa-Fluor 488 
secondary antibody (Molecular probesTM, Carlsbad, USA). Nuclei were counterstained with 
TO-PRO3. Finally, the slides were washed, covered, and sealed. Labelled sections were 
observed using a Leica SP2 Confocal Microscope.  
 
The hVEGF expression in myocardium was also detected. Firstly, the hVEGF was stained 
following the protocol and a goat polyclonal anti-Troponin T primary antibody (Santa Cruz, 
Dallas, USA) was applied to the sections. Secondly, a donkey anti-goat Alexa-Fluor 568 
(Molecular probes
TM
, Carlsbad, USA) was utilized. Counterstaining was achieved by TO-
PRO3 nuclear staining. Finally, the slides were washed, covered, and sealed. The samples 
were analyzed using a LSM 780 confocal microscopy (Carl Zeiss, Jena, Germany). 
 
2.14 Immunohistochemical analysis for GFP distribution and 
expression in vivo 
For immunohistochemical detection of GFP expression, frozen transverse tissue sections (8 
µm thick) of hearts from MI-Magnet
+
MNBs/AdGFP and MI-Magnet
-
MNBs/AdGFP (n = 4 for 
each group) were selected. The slides were allowed to dry for 20 minutes at room 
temperature. Then a boundary between each two sections on the same slide was drawn by 
DAKOCytomation pen. The tissue sections were fixed by covering with 1% 
paraformaldehyde for 10 minutes. After fixing, the samples were washed twice with PBS. 
One drop of protein block solution was added to each slide to cover the tissue section. Then 
the tissue sections were incubated with goat anti-GFP conjuganted FITC antibody (Abcam, 
Cambridge, UK) at 4°C overnight. Nuclei were counterstained with TO-PRO3. Finally, the 
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slides were washed, covered with the coverslips and sealed. Labelled sections were observed 
using a Leica SP2 Confocal Microscope.  
2.15 Prussian blue staining for MNBs distribution in vivo 
Frozen transverse tissue sections (8 µm thick) of hearts from MI-Magnet
+
MNBs/AdGFP and 
MI-Magnet
-
MNBs/AdGFP (n = 4 for each group) were selected. The slides were allowed to 
dry for 20 minutes at room temperature. Then a boundary between each section on the same 
slide was drawn by DAKOCytomation pen. The tissue sections were fixed by covering with 
10% formalin (Sigma Aldrich, St. Louis, USA) for 10 minutes. Afterwards, slides were 
rinsed by the distilled water twice. Meanwhile, equal parts of 10% hydrochloric acid (Sigma 
Aldrich, St. Louis, USA) and 5% potassium ferrocyanide (Sigma Aldrich, St. Louis, USA) 
were mixed immediately. Slides were put into the mixed solution for 20 minutes. After 
staining, slides were rinsed twice with the distilled water. Then slides were stained with 1% 
eosin solution (Sigma Aldrich, St. Louis, USA) for 5 minutes. After staining, slides were 
rinsed twice with distilled water. Finally, the slides were dehydrated through 95% and 100% 
alcohol (Sigma Aldrich, St. Louis, USA) and then the slides were left in 100% xylene (Sigma 
Aldrich, St. Louis, USA) until mounting. Labelled sections were observed using a Leica SP2 
Confocal Microscope.    
     
2.16 Left Ventricular Catheterization for heart function evaluation  
4 weeks after surgery, rats underwent pressure-volume (PV) loop measurements according 
to the protocol of CardioDynamics BV (CD Leycom, Zoetermeer Netherlands). Data were 
collected with the Millar PV System (Ultra-Miniature PV Catheter (model SPR-1030), Millar 
Pressure Conductance Unit (model MPCU-200) and Millar Power Lab data-acquisition 
hardware; emka Technologies, Pairs, France). Calibration of pressure and volume was 
performed by equating the minimal and maximal conductances with minimal (0 mmHg) and 
maximal (100 mmHg) pressures as well as minimal and maximal blood volumes received 
from venous circulation. Firstly, the jugular vein was opened with fine forceps and mini-
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scissors under microscopy. Subsequently, the tube cannula was inserted into the jugular vein 
and 200 µl heparin (500 g/ml, Sigma Aldrich, St. Louis, USA) was injected into body. 
Secondly, the carotis was opened with fine forceps and mini-scissors under microscopy and a 
catheter with both conductance electrodes was inserted in to the carotis gently. The catheter 
was pushed forward and back till it was placed behind the aorotic valve and the characteristic 
heart pressure curve was visible. PV loops were recorded under normal conditions (baseline) 
followed by stress conditions mediated by intravenous dobutamine administration (10 µg/kg, 
Sigma Aldrich, St. Louis, USA). Volume signal was corrected by measurement of wall 
conductance (parallel volume) via hypertonic saline (5%) injection. Data were analyzed with 
IOX Version 1.8.3.20 software (emka Technologies, Pairs, France). As histological 
evaluation on hearts in different cardiac phases can lead to under- or overestimation of the 
analysis such as capillary density, infarct size, fibrosis etc, after PV loop measurements, rats 
were euthanized by 5% KCl perfusion. The overdose of KCl may cause cardiac conduction 
blocks and stop the heartbeat at the diastolic phase so that the histological analysis was 
performed in the diastolic phase of the heart.  
 
2.17 Determination of functional perfusion and capillary density 
Hearts were isolated and aorta was cannulated using a 20 g steel cannula. After cannulation 
of the aorta, the hearts were perfused at constant pressure in the Langendorff mode by an 
aortic cannula with 7.5 mg/ml of Fluorescein Lycopersicon Esculentum (tomato) lectin 
(Linaris, Mannheim, Germany) suspended in 0.2-mm-filtered Krebs-Henseleit buffer (117 
mM NaCl, 24 mM NaHCO3, 11.5 mM D-[t]-glucose, 3.3 mM KCl, 1.25 mM CaCl2, 1.2 mM 
MgSO4 and 1.2 mM KH2PO4) equilibrated with 95% O2 and 5% CO2 followed by 20 ml 
Krebs-Henseleit buffer alone. Tomato lectin binds to the surface N-acetylglucosamine 
oligomers of endothelial cell lining perfused vessels, thereby delineating perfused 
vasculature. Direct contact of tomato lectin with endothelial cells is required for labeling. 
Therefore, vessels that are not perfused will not be labeled with tomato lectin. Finally hearts 
were embedded in O.C.T TM Compound (Tissue-Tek®, Würzburg, Germany) and snapfrozen 
in liquid nitrogen. To evaluate the capillary density, the infarct area was then divided into 4 
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horizontal levels from top to bottom. 8 μm thick cryostat sections were stained with TO-
PRO3. The sections were analysed within the border zone of the heart. Capillaries were 
counted in 5 randomly chosen fields from the border zone (630×). Capillary density was 
expressed as capillaries per mm
2
. 
2.18 Immunohistochemical staining of CD31 for determination of 
capillary density 
The capillary density was assessed at 4 weeks after surgery by counting the number of 
capillaries of the heart sections. Firstly, frozen transverse tissue sections (8 μm) of hearts 
from each group were dried out at room temperature for 20 minutes. Then a boundary 
between each two sections on the same slide was drawn by DAKOCytomation pen. Tissue 
sections were fixed by covering with 1% paraformaldehyde for 10 minutes. After fixing, the 
samples were washed twice with PBS. One drop of protein block solution was added to each 
slide to cover the tissue section. Then the tissue sections were incubated with polyclonal goat 
anti-CD31 antibody (Santa Cruz, Dallas, USA) at 4°C overnight. Subsequently, the sections 
were incubated with donkey anti-goat Alexa-Fluor 568 (Molecular probes
TM
, Carlsbad, USA) 
conjugated secondary antibody. Nuclei were counterstained with DAPI (Molecular probes
TM
, 
Carlsbad, USA) or To-PRO3. Finally, the slides were washed, covered, and sealed. Labelled 
sections were observed using a Leica SP2 Confocal Microscope. Five sections within the 
border zone of each group were analyzed. Capillaries were counted in randomly chosen 
fields from the border zone. Results were expressed as capillaries per high power field 
(HPF). 
 
2.19 Infarct size and wall thickness analysis 
Heart sections of 4 horizontal infarct levels (8 µm) were stained with Fast Green (Sigma 
Aldrich, St. Louis, USA) and Sirius Red (Division Chroma, Hamburg, Germany). Frozen 
transverse tissue sections (8 µm) of hearts from each group were selected. The slides were 
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dried out for 20 minutes at room temperature. Then the tissue sections were fixed by 
covering with 10% formalin for 10 minutes. After fixing, slides were put into 0.1% Sirius 
Red (Sigma Aldrich, St. Louis, USA) for 3 minutes to stain fibrosis red, then transferred into 
0.1% Fast Green (Sigma Aldrich, St. Louis, USA) for 10 minutes to stain cardiac tissue. 
After staining, slides were rinsed twice in distilled water. Then slides were stained with 1% 
eosin (Sigma Aldrich, St. Louis, USA) for 5 minutes and again rinsed twice in distilled water. 
Finally, the slides were dehydrated through 95% and 100% alcohol in sequence and then 
slides were left in xylene until mounting. Labelled sections were observed using a Leica SP2 
Confocal Microscope. The infarction size and wall thickness were analyzed using 
computerized planimetry (Axio Vision LE Rel. 4.5 software; Zeiss, Jena, Germany).  
 
2.20 Fibrosis analysis 
To evaluate fibrosis, LV transverse tissue sections were stained with Sirius Red. Slides were 
analysed for positive regions of collagen deposition in the infarct border zone using 
computerized planimetry. Sirius Red positive regions were examined in 5 randomly chosen 
fields per section (one section per level; 1000×). Fibrosis was expressed as the ratio of 
collagen deposition to myocardial tissue in percentage. 
 
2.21 Determination of arteriole density 
For immunohistochemical detection of arteriole density, heart sections (8 µm) from all 
groups were selected. Slides were dried out for 20 minutes at room temperature. Then a 
boundary between each two sections on the same slide was drawn by DAKOCytomation pen. 
The tissue sections were fixed by covering with 1% paraformaldehyde for 10 minutes. After 
fixing, the samples were washed twice with PBS. One drop of protein block solution was 
added to each slide to cover the tissue section. Then the tissue sections were incubated with 
polyclonal rabbit anti-α-SMA (Abcam, Cambridge, UK) primary antibody at 4°C overnight. 
Subsequently, all sections were incubated with goat anti-rabbit Alexa-Fluor 568 (Molecular 
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probes
TM
, Carlsbad, USA) conjugated secondary antibody. Nuclei were counterstained with 
TO-PRO3. Finally, the slides were washed, covered, and sealed. Labelled sections were 
observed using a Zeiss LSM 780 Confocal Microscope. The sections were analysed in the 
border zone of the hearts. Arteriole density was assessed by counting the number of 
arterioles in 5 border zone randomly-chosen fields (630×). Results were expressed as 
arterioles per mm
2
. 
2.22 Experimental design of matrigel for cardiac repair 
For this study, Lewis rats (male, 250 ± 5 g) were purchased from Charles River Laboratories 
(Sulzfeld, Germany). The federal animal care committee of the Landesamt für Landwirtschaft, 
Lebensmittelsicherheit und Fischerei (Mecklenburg-Vorpommern, Germany) approved the 
study protocol (approval number M-V/TSD/7221.3-1.1-044/09). All animal procedures are in 
accordance with requirements of the Animal Care and Use Committee of the Medical School, 
University of Rostock. Details were described in 2.10. Rats were randomly assigned to 3 
groups as follows: sham operation, n = 6; MI-matrigel (MI-M), n = 11; and MI-PBS, n = 11. 
The animals in all groups were used for histopathological analysis and evaluation of heart 
function 4 weeks after MI (Figure 7). 
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Figure 7: Experimental design. (A) In vivo experimental design. (B) After LAD-ligation the 
rats received the matrigel injection into the areas of infarcted myocardium. 
 
B 
A 
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2.23 MI and local matrigel administration  
Rat MI model was described in 2.10. Immediately after LAD ligation, rats received 5 
intramyocardial injections of either matrigel or PBS of a total volume of 250 μl. 5 injection 
sites were chosen along the border of the infarcted cardiac tissue with a 31-gauge needle (BD 
Biosciences, New Jersey, USA). Sham operated rats underwent identical surgical procedures 
without permanent LAD ligation (Figure 7B). 
 
2.24 Immunohistochemical staining for c-kit+ cells 
For immunohistological detection of c-kit+ stem cells, frozen transverse tissue sections (8 μm) 
of hearts from the MI-PBS group and the MI-M group were dried out at room temperature 
for 20 minutes. Then the air dried samples on the same slide were separated by drawing a 
boundary by DAKOCytomation pen. The tissue sections were fixed by covering with 1% 
paraformaldehyde for 10 minutes. After fixing, the samples were washed twice with PBS. 
One drop of protein block solution was added to each slide to cover the tissue section. Then 
the tissue sections were incubated with rabbit anti-c-kit antibody (Santa Cruz, Dallas, USA) 
overnight 4°C. Subsequently, the sections of the MI-PBS group and the MI-M group were 
incubated with donkey anti-rabbit Alexa-Fluor 488 (Molecular probesTM, Carlsbad, USA) 
conjugated secondary antibody. Nuclei were counterstained with TO-PRO3. Finally, the 
slides were washed, covered, and sealed. Labelled sections were observed using a Leica SP2 
Confocal Microscope. The number of c-kit+ cells was counted in 5 randomly-chosen fields 
(630×). Results were expressed as c-kit+ cells per HPF. 
 
2.25 Immunohistochemical staining for CD34+ cells 
For immunohistological detection of CD34+ stem cells, frozen transverse tissue sections (8 
μm) of hearts from the MI-PBS group and the MI-M group were dried at room temperature 
for 20 minutes. Then the air-dried samples on the same slides were separated by drawing a 
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boundary by DAKOCytomation pen. And the tissue sections were fixed by covering with 1% 
paraformaldehyde for 10 minutes. After fixing, the samples were washed twice with PBS. 
One drop of protein block solution was added to each slide to cover the tissue section. Then 
the tissue sections were incubated with goat anti-CD34 antibody (Santa Cruz, Dallas, USA) 
at 4°C overnight. Subsequently, the sections of the MI-PBS group and the MI-M group were 
incubated with donkey anti-goat Alexa-Fluor 488 (Molecular probesTM, Carlsbad, USA) 
conjugated secondary antibody. Nuclei were counterstained with TO-PRO3. Finally, the 
slides were washed, covered, and sealed. Labelled sections were observed using a Leica SP2 
Confocal Microscope. The number of CD34+ cells were counted in 5 randomly zone 
randomly-chosen fields (630×). Results were expressed as c-kit+ cells per HPF.
 
  
2.26 Statistical analyses 
Data are expressed as mean values ± standard error of the mean (SEM) or values ± 
standard deviation (SD). One-way analysis of variance was employed for comparing 
differences between groups. Statistically differences were considered as significant at P 
values < 0.05. 
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3   Results
2
 
3.1 HUVECs vascular network formation 
The effect of AdhVEGF on HUVECs tube formation was examined. The formation of 
capillary-like networks on matrigel was increased significantly in the AdhVEGF treated group 
(Figure 8). Compared to the control group, the mean tube length of the HUVECs network 
increased more than 50% in the presence of AdhVEGF (Figure 8). The data proved that 
AdhVEGF acts as an angiogenic factor to promote endothelial cell tube formation and sprouting 
in vitro. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Tube-like network formation assay. (A) Two-dimensional tube formation was 
performed in the presence or absence of AdhVEGF on matrigel. (B) The formation of capillary-
like networks on matrigel was enhanced significantly in the AdhVEGF treated group. Data are 
                                                 
2
 Own figures from [173] and [180] were included after obtaining permission from Public Library of Science 
(PLOS) ONE and Journal of Cellular and Molecular Medicine (JCMM) / John Wiley & Sons Ltd publishing 
houses. 
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expressed as mean ± SEM. * P < 0.05 versus control group. (A) Scale bar = 40 µm. [AdhVEGF 
group, n = 4; control group, n = 4] 
 
3.2 MNBs/Ad complexes characterization 
After the presentation of complexes, the ZetaPLAS analyzer was used to evaluate the 
diameter of MNBs/Ad complexes. The actual size of Ad is 90 nm. Due to hydration, stable 
aqueous layers form around the Ad which increased the average diameter of Ad to 100-200 
nm. The average diameter of MNBs/Ad complexes was larger than that of the naked Ad, 
which may be due to MNBs forming a shell around the Ad. Firstly, 8 × 10
7
 pfu Ad were 
distributed into tubes, then different doses of MNBs were added to the prepare complexes 
with to different MNB/Ad ratios. Figure 9 shows that by increasing doses of MNBs, free Ad 
group was diminished and the number of MNBs/Ad complexes was increased. At 16µl of 
MNBs, approximately 100% of measured particles were MNBs/Ad complexes, whereas free 
Ad particles were no longer detectable. This result indicated that at an MNB dose of 16 µl, 
with an Ad amount 8 × 10
7
 pfu of Ad, and, thus, a MNBs/Ad ratio of 2, Ad can completely 
bound to MNBs.  
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Figure 9: (A) Characterization of MNBs/Ad complexes. The amount of Ad used in the 
experiment was 8 × 10
7
 pfu and MNBs doses were varied. MNBs/Ad complexes increased 
but the free Ad decreased with higher MNBs doses. Close to 100% of MNBs dose were 
combined with Ad at a dose of 16 µl. Data are expressed as mean ± SD. [n = 3 for each group] 
(B) Schematic of MNBs/Ad complexes formation. (Figure 9A quoted from [
173
]) 
 
3.3 HUVECs transduction efficiency and cytotoxicity of MNBs/Ad 
complexes in vitro  
To investigate the impact of an external magnetic field on cell transduction, the efficiency of 
MNBs/Adluc complexes was assessed in HUVECs by using luciferase as reporter gene 
(Figure 10A). As HUVECs are primary endothelial cells, they provide a suitable model to 
evaluate the transduction capacity of MNBs/Adluc complexes on endothelium in vivo. The 
transduction efficiency was mediated by different doses of MNBs and Adluc (Adluc without 
MNBs were used as a control group) and the transduction efficiency was related to the 
binding ratio of MNBs to Ad. It was found that the coupling of MNBs to Adluc complexes 
improved the transduction efficiency in HUVECs considerably. At 16 µl MNBs, 8 × 10
7
 pfu
 
Ad and a MNBs/Ad ratio of 2, HUVECs transduction achieved maximal efficiency. The peak 
transduction efficiency of HUVECs was 50 fold higher than transduction efficiency of Ad 
B 
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alone. The in vitro cytotoxicity of MNBs/Adluc was also evaluated in HUVECs by using 
MTT cellular metabolic activity assay. Relative viabilities (MNBs/Adluc relative to Adluc 
alone) were decreased and the cytotoxicity was increased by increasing MNBs doses or Ad 
amounts (Figure 10A). However, at optimal parameters for MNBs/Ad complexes (16 µl 
MNBs, 8 × 10
7
 pfu
 
Ad and a MNBs/Ad ratio of 2), the cellular metabolic activity was still 
higher than 85% (Figure 10B). These results suggested that transduction with optimized 
MNBs/Ad complexes did not induce obvious cytotoxicity and the optimized parameters of 
the complexes can be used for gene delivery in vitro or in vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
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Figure 10: Transduction and cytotoxicity of MNBs/Adluc complexes in HUVECs. (A) In 
vitro luciferase expression of HUVECs transduced by MNBs/Adluc complexes for evaluation 
of magnetically controlled gene delivery. Relative light units were normalized to the protein 
content of cell lysates. At 16 µl MNBs, 8 × 10
7
 pfu
 
Ad and a MNBs/Ad ratio of 2, 
transduction efficiency was enhanced significantly compared to Adluc alone treated groups. 
(B) In vitro MTT evaluation of HUVECs transduced by MNBs/Adluc complexes. The amount 
of Ad was expressed as pfu and MNBs doses were varied. Values are presented as a 
percentage of viability of MNBs/Adluc treated cells relative to that of Adluc treated cells 
(control).  Data are expressed as mean ± SD. * P < 0.05 versus Adluc alone treated groups. [n 
= 6 for each group] (Figure 10 redrawn after [
173
]) 
 
3.4 Magnetic field guidance in vitro   
The cells can be rendered super-paramagnetic, after they take up the MNBs, and therefore 
become accessible for magnetic force-guided targeting 
143
. Figure 11 shows HUVECs which 
were fixed and stained for the lacZ gene expression. HUVECs were transduced with 
MNBs/AdLacZ, and cultured with gentle agitation, with three cylindrical magnets positioned 
under the plate prior to transduction. As a control, MNBs/AdLacZ-transduced HUVECs were 
cultured without application of magnetic field. After 24 hours of culture, cells were stained 
B 
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with X-gal. LacZ gene expression formed a well-defined three-spot pattern (Figure 11A) and 
MNBs/AdLacZ transduced cells were retained in the confined areas above the magnets (Figure 
11B). Figure 12 shows a similar phenomenon. The MSCs transduction efficiency in the area 
under the magnet exceeded 80% and in the area far from the magnetic force was below 4%. 
Moreover, a clear border was visible between the areas with and without magnetic field 
(Figure 12C). GFP reporter gene expression is shown in Figure 13. The result has shown 
that nearly all Ad have been bound to MNBs. The magnetic field area displayed higher GFP 
expression, whereas transduction efficacy was comparatively lower in the areas without 
magnetic field and, thus, fewer MNBs. These phenomena indicated that MNBs can be used 
to position cells by the external magnetic field even in the presence of hydrodynamic forces, 
and that MNB-based gene expression has the potential for in vivo use. 
 
 
Figure 11: In vitro, targeted attachment of HUVECs after transduction with MNBs/AdLacz 
complexes. (A) The transduced HUVECs formed a three-spot pattern determined by the 
locations of the magnets. (B-C) The expression of LacZ reporter gene in the adjacent area 
influenced by the external magnetic field and in an area far from the magnetic field. (D) The 
LacZ reporter gene expression was detected and a clear border was visible between the areas 
with and without magnetic field. (A) Scale bar = 2 mm; (B-D) Scale bar = 100 µm. (Figure 
11 quoted from [
173
]) 
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Figure 12: In vitro, targeted attachment of MSCs after transduction with MNBs/AdLacZ 
complexes. (A-B) The expression of LacZ reporter gene in the adjacent area influenced by 
the external magnetic field and in an area far from the magnetic field. (C) The reporter gene 
LacZ expression formed a clear border between the transduced and un-transduced MSCs. (A-
C) Scale bar = 100 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: In vitro GFP expression of MSCs transduced by MNBs/AdGFP complexes and 
evaluation of transduction specificity. The reporter gene GFP was expressed in the confined 
area influenced by the external magnetic field. GFP expression formed a clear border 
between the areas with and without magnetic field. (A-B) Scale bar = 100 µm. 
 
100 μm 
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3.5 Distribution and expression of hVEGF in vivo   
Redistribution and expression of  hVEGF gene were detected and evaluated 7 days after the 
MNBs/AdhVEGF complexes systemic delivery. Here, a markedly higher hVEGF gene 
expression in myocardium was detected in the MI-M
+
MNBS/AdhVEGF group (Figure 14A). 
The hVEGF gene expression in different organs including heart, liver, spleen, lung, and 
kidney was determined by Real-Time PCR. Placement of a permanent magnet at the 
epicardium close to the heart resulted in a significant redistribution of the MNBs/AdhVEGF 
complexes, whereas the number of complexes in the liver was reduced compared to the MI-
M
-
MNBS/AdhVEGF group (Figure 14B). Figure 14C shows a scheme of systemic delivery of 
MNBs/AdhVEGF complexes, guidance by an external magnetic force, targeting towards, and 
gene expression in the ischemic myocardium.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Real-Time PCR and immunohistochemistcal examination of magnetically 
controlled gene distribution and expression after systemic administration of MNBs/AdhVEGF 
complexes. (A) In MI-M
+
MNBs/AdhVEGF group, hVEGF positive transduced cells were 
detected in the infarcted myocardium. Sections were stained with anti-hVEGF antibody (blue) 
and nuclei were stained with TO-PRO3 (red). (B) Real-Time PCR analysis for hVEGF gene 
expression in hearts, livers, spleens, lungs and kidneys in MI-M
+
MNBs/AdhVEGF, MI-M
-
D 
B 
C 
 
A 
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MNBs/AdhVEGF and the MI-saline groups. The number of complexes in the heart was 
increased significantly compared to the MI-M
-
MNBS/AdhVEGF group * P < 0.05 versus hearts 
in MI-M
-
MNBs/AdhVEGF, # P < 0.05 versus livers in MI-M
-
MNBs/AdhVEGF. (A) Scale bar = 
15 µm; (B) Scale bar = 6 µm. [MI-M
+
MNBs/AdhVEGF, n = 4; MI-M
-
MNBs/AdhVEGF, n = 4; 
MI-Saline, n = 4] (Figure 14D quoted from [
173
].) 
3.6 Prussian blue staining of MNBs in infarcted rat heart 
In magnet positive groups, Prussian blue–positive signals were detected at the infarct site and 
the border region in tissue sections (Figure 15). Sections corresponding to the Prussian 
Blue–positive areas were positively tested for the presence of GFP or hVEGF protein 
expression in the magnet positive groups (Figure 14A and Figure 16). In contrast, little 
Prussian blue-positive signals were found in the magnet negative group. This result further 
proved that MNBs/Ad can be guided and attracted by an external magnetic field. The binding 
of Ad by biotin/Strepavidin with MNBs proved to be stable under in vivo conditions. The 
MNBs/Ad complexes were able to target the therapeutic gene/hVEGF towards the infarct 
region to promote the recovery of ischemic heart function. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Analysis of MNBs in infarcted myocardium. In the MI-M
+
MNBs/Ad group, 
Prussian blue staining demonstrated a large number of MNBs localized in the infarcted 
myocardium. MNBs were stained with Prussian blue (blue) and cardiac muscle was stained 
with eosin (red). (A) Scale bar = 50 µm; (B) Scale bar = 20 µm. 
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3.7 Expression of GFP in infarcted rat heart   
Immunohistochemical staining with anti-GFP antibody proved that 24 hours as well as 7 
days after systemic administration of MNBs/AdGFP complexes, strong GFP expression was 
present in the myocardium in the presence of the external magnetic field group. This finding 
demonstrated that MNBs/Ad complexes can be positioned in the infarcted myocardium by 
magnetic targeting. 
Figure 16: Immunohistochemical analysis for GFP gene expression in infarcted myocardium. 
In the MI-M
+
MNBs/AdGFP group, GFP positive cells were localized in the infarcted 
myocardium. Sections were stained with anti-GFP antibody (green) and nuclei were stained 
with TO-PRO3 (red). Scale bar = 15 µm. (Figure 16 redrawn after [
173
]) 
3.8 Localization of hVEGF expression in infarcted rat heart 
In the MI-M
+
MNBs/AdhVEGF group, a double immunohistochemical staining with anti-
hVEGF and an antibody against the endothelial marker CD31 (Figure 17) showed that 
AdhVEGF can transduce endothelium successfully. The overexpression of hVEGF may 
promote endothelial cell proliferation and anti-apoptosis and play an important role in 
replacement of cells lost in MI. Furthermore, localized expression of hVEGF was found in 
capillaries by immunohistochemical staining with anti-hVEGF and fluorescein tomato lectin 
(Figure 18). These results were consistent with Figure 25 which indicated that hVEGF 
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expression in the border zone of the infarcted heart could increase capillary density. In 
addition, hVEGF expression in cardiac Troponin T-positive cells was detected in the MI-
M
+
MNBs/AdhVEGF group (Figure 19).  
 
Figure 17: Localization of the expression of a systemically applied hVEGF in endothelium. 
Sections from the MI-M
+
MNBs/AdhVEGF group showed several transduced cells positive for 
hVEGF interspersed in the luminal lining of the vessel. Sections were stained with anti-
hVEGF antibody (yellow), blood vessels were stained with anti-CD31 (red) and nuclei were 
stained with DAPI (blue). Scale bar = 10 µm. (Figure 17 quoted from [
173
])  
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Figure 18: Localization of the expression of a systemically applied hVEGF in the capillaries. 
Sections from the MI-M
+
MNBs/AdhVEGF group showed AdhVEGF transduced cells positive for 
hVEGF in the capillaries. Sections were stained with anti-hVEGF antibody (red), capillaries 
were stained with fluorescein tomato lectin (green), and nuclei were stained with TO-PRO3 
(blue). (A) Scale bar = 20 µm; (B) Scale bar = 2 µm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Occasionally hVEGF co-localized with cardiac troponin positive cells in the 
ischemic myocardium. Sections were stained with anti-hVEGF antibody (yellow) and anti-
Troponin T antibody (red). Nuclei were stained with TO-PRO3 (blue). (A-B) Scale bar = 10 
µm; (C-E) Scale bar = 2 µm. (Figure 19 quoted from [
173
])  
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3.9 Inflammatory response analysis after injection of MNBs/Ad 
complexes 
CD8
+
T cells were mobilized to the peripheral blood after intravenous injection of MNBs/Ad 
complexes in the MI-M
+
MNBs/AdhVEGF group in comparison to the other groups 7 days after 
MI. Figure 20 shows that the average percentage of CD8
+
T cells in peripheral blood was 
increased compared to the other groups, As CD8
+
T cells serve as a host defense against Ad 
transduction. The accumulation of MNBs/Ad complexes in to the heart by the external 
magnetic gradient field guiding would induce the inflammatory response and stimulate the 
mobilization of CD8+ T cells to the peripheral blood 
181
.  
 
 
 
 
 
 
Figure 20: Inflammatory response after systemic delivery of MNBs/AdhVEGF complexes. 
Data are shown the results of FACS analyses of mononuclear cells from peripheral blood in 
the different groups. CD8
+ 
T cells of peripheral blood were significantly enhanced in the MI-
M
+
MNBs/AdhVEGF group compared to sham and other MI treated groups. Data are mean 
values ± SEM. * P < 0.05 MI-M
+
MNBs/AdhVEGF versus sham, # P < 0.05 versus MI-saline, 
ζ  P < 0.05 versus MI-MNBs and τ  P < 0.05 versus MI-M-MNBs/AdhVEGF. [MI-
                                                                                                                                                                                         
                                                                                                                                                                                          Results                                                                                                                                                                                                                                                                             
58 
 
M
+
MNBs/AdhVEGF, n = 4; MI-M
-
MNBs/AdhVEGF, n = 4; MI-MNBs, n = 4; MI-Saline, n = 4 
and sham-operated, n = 4] (Figure 20 quoted from [
173
]) 
 
3.10 MNBs/AdhVEGF complexes injection improved cardiac function 
In the MI-M
+
MNBs/AdhVEGF group, systolic and diastolic properties of the infarcted LV were 
improved both at baseline condition and under stress induction compared to the other groups. 
Hemodynamic measurements are summarized in Table 1. Left ventricular peak rate of 
maximum pressure rise (dp/dt max) and peak rate of maximum pressure decline (-dp/dt 
max), two commonly used indexes of myocardial contractility were markedly decreased in 
all MI treated groups compared to the sham group (Table 1). However, in the MI-
M
+
MNBs/AdhVEGF group, dp/dt max was significantly enhanced at baseline and under stress 
when compared to other MI treated groups (Figure 21). Furthermore, I observed an obvious 
enhancement in the -dp/dt max in the MI-M
+
MNBs/AdhVEGF group, demonstrating an 
increased diastolic relaxation of the myocardium in this group. Accordingly, maximum 
pressure (P max) was significantly higher both at baseline and under dobutamine stress in 
the MI-M
+
MNBs/AdhVEGF group. Heart rate was only moderately increased, in contrast to 
other MI treated group (Figure 22). hVEGF treatment produced a considerable increase of 
LV ejection fraction (EF) compared to MI-M
-
MNBs/AdhVEGF and other MI treated groups 
under stress induction (Figure 21). Thus, targeted hVEGF treatment significantly enhanced 
contractility, decreased stiffness and increased elasticity of the LV. 
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Figure 21: Intravenous MNBs/AdhVEGF injection restored cardiac function 4 weeks after MI 
assessed by catherization. Left ventricular function both at baseline and under the stress 
condition revealed the increments of left ventricular dp/dt max and -dp/dt max under baseline 
and dobutamine stress compared to the MI-M
-
MNBs/AdhVEGF group. Moreover, the EF was 
enhanced under dobutamine stress compared to the MI-M
-
MNBs/AdhVEGF group. Data are 
mean values ± SEM. * P < 0.05 MI-M
+
MNBs/AdhVEGF versus sham, # P < 0.05 versus MI-
saline, ζ P < 0.05 versus MI-MNBs and τ P < 0.05 versus MI-M-MNBs/AdhVEGF. [MI-
M
+
MNBs/AdhVEGF, n = 10; MI-M
-
MNBs/AdhVEGF, n = 10; MI-MNBs, n = 10; MI-Saline, n = 
10 and sham-operated, n = 5]  (Figure 21 quoted from [
173
]) 
                                                                                                                                                                                         
                                                                                                                                                                                          Results                                                                                                                                                                                                                                                                             
60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Intravenous MNBs/AdhVEGF injection restored cardiac function 4 weeks after MI, 
as assessed by catherization. Left ventricular function at both baseline and stress conditions 
revealed the increments of left ventricular P max and heart rate under baseline and 
dobutamine stress compared with the MI-M
-
MNBs/AdhVEGF group. Data are mean values ± 
SEM. * P < 0.05 MI-M
+
MNBs/AdhVEGF versus Sham, # P < 0.05 versus MI-saline, ζ P < 
0.05 versus MI-MNBs and τ P < 0.05 versus MI-M-MNBs/AdhVEGF. [MI-M
+
MNBs/AdhVEGF, 
n = 10; MI-M
-
MNBs/AdhVEGF, n = 10; MI-MNBs, n = 10; MI-Saline, n = 10 and sham-
operated, n = 5] 
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Table 1: (A) Hemodynamics of the LV under baseline condition 4 weeks after MI. (B) 
Hemodynamics of the LV under stress condition 4 weeks after MI. Values are represented as 
mean ± SEM, P max means maximum pressure; dp/dt indicates peak rate of maximum 
pressure rise (dp/dt max) and decline (-dp/dt max); EDV, end diastolic volume; ESV, 
endsystolic volume; SV, stroke volume; EF, ejection fraction; and HR, heart rate. Data are 
mean values ± SEM. * P < 0.05 MI-M
+
MNBs/AdhVEGF versus Sham, # P < 0.05 versus MI-
saline, ζ P < 0.05 versus MI-MNBs and τ P < 0.05 versus MI-M-MNBs/AdhVEGF. [MI-
M
+
MNBs/AdhVEGF, n = 10; MI-M
-
MNBs/AdhVEGF, n = 10; MI-MNBs, n = 10; MI-Saline, n = 
10; and sham-operated, n = 5]  (Table 1A quoted from [
173
]) 
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3.11 MNBs/AdhVEGF complexes injection increased the infarct wall 
thickness and reduced the fibrosis  
LAD ligation results in MI and causes post-infarction cardiac remodelling which plays an 
important role as a compensatory mechanism of heart failure. Remodelling exhibits typical 
histological changes including progressive ventricular chamber dilation, thinning of the left 
ventricular wall (Fast Green), extensive collagen deposition (Sirius Red), hypertrophy, 
fibrosis, and, cardiac cell apoptosis and necrosis. Fibrosis results in extensive collagen 
deposition (Sirius Red). Representative heart sections of 4 weeks after MI in different groups 
are shown in Figure 23 and Figure 24. Although the infarct size did not differ significantly 
among different MI treated groups, LV infarct wall thickness was significantly increased in 
the MI-M
+
MNBs/AdhVEGF group compared to other MI treated groups (Figure 23 B). 
Computerized planimetry of heart cross sections indicated that more collagen deposition 
occurred in all MI treated groups (Figure 24). However, the M
+
MNBs/AdhVEGF group 
showed markedly decreased collagen deposition compared to the MI-M
-
MNBs/AdhVEGF 
group and other MI treated groups. (Figure 24 B). 
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Figure 23: Effects of intravenous MNBs/AdhVEGF injection on cardiac remodelling 4 weeks  
after MI. (A) Representative heart cross sections stained with Sirius Red (red, fibrosis) and 
Fast Green (green, myocyte) from rats. (B) Infarct wall thickness was significantly increased 
in the MI-M
+
MNBs/AdhVEGF group compared with other MI treated groups. Data are mean 
values ± SEM. * P < 0.05 MI-M
+
MNBs/AdhVEGF versus sham, # P < 0.05 versus MI-saline, ζ 
P < 0.05 versus MI-MNBs and τ P < 0.05 versus MI-M-MNBs/AdhVEGF. (A) Scale bar = 3 
mm. [MI-M
+
MNBs/AdhVEGF, n = 5; MI-M
-
MNBs/AdhVEGF, n = 5; MI-MNBs, n = 5; MI-
Saline, n = 5 and sham-operated, n = 5] (Figure 23 quoted from [
173
])  
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Figure 24: Fibrosis. A, Representative Sirius Red (red, fibrosis) and Fast Green (green, 
myocyte) immunohistochemical staining of the border zone. B, Ratio of collagen deposition 
declined in the MI-M
+
MNBs/AdhVEGF  group compared to other MI treated groups. Data are 
presented as mean values ± SEM. # P < 0.05 versus MI-saline, ζ P < 0.05 versus MI-MNBs 
and τ P < 0.05 versus MI-M-AdhVEGF. (A) Scale bar = 20 µm. [MI-M
+
MNBs/AdhVEGF, n = 4; 
MI-M
-
MNBs/AdhVEGF, n = 4; MI-MNBs, n = 4; MI-Saline, n = 4 and sham-operated, n = 4] 
(Figure 24 quoted from [
173
]) 
 
3.12 MNBs/AdhVEGF complexes injection enhanced capillary density 
Capillary density was analysed by immunohistochemical staining using anti-tomato lectin 
and anti-CD31 antibodies (Figure 25 A and Figure 26 A) 4 weeks after MI. Capillary 
density in the border zone was significantly decreased in all MI treated animals. However, 
the MI-M
+
MNBs/AdhVEGF group showed a higher capillary density evident from both tomato 
lectin perfusion staining and anti-CD31 antibody staining compared to other MI treated 
groups (Figure 25 B and Figure 26 B).  
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Figure 25: Intravenous MNBs/AdhVEGF administration induced angiogenesis 4 weeks after 
MI. (A) Representative fluorescein tomato lectin perfusion staining at the border area of 
infarcted myocardium. (B) Capillary density in the border zone of the LV was significantly 
higher in the MI-M
+
MNBs/AdhVEGF group compared to other MI treated groups. Data are 
mean values ± SEM. # P < 0.05 versus MI-saline, ζ P < 0.05 versus MI-MNBs and τ P < 
0.05 versus MI-M
-
AdhVEGF. (A) Scale bar = 15 µm. [MI-M
+
MNBs/AdhVEGF, n = 4; MI-M
-
MNBs/AdhVEGF, n = 4; MI-MNBs, n = 4; MI-Saline, n = 4 and sham-operated, n = 4] (Figure 
25 quoted from [
173
]) 
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Figure 26: Intravenous MNBs/AdhVEGF delivery induced angiogenesis 4 weeks after MI. (A) 
Representative anti-CD31 staining at the infarct border zone. (B) Capillary density at the 
border zone of the LV was significantly higher in the MI-M
+
MNBs/AdhVEGF group compared 
to other MI treated groups. Data are mean values ± SEM. # P < 0.05 versus MI-saline, ζ P < 
0.05 versus MI-MNBs and τ P < 0.05 versus MI-M-AdhVEGF. (A) Scale bar = 30 µm. [MI-
M
+
MNBs/AdhVEGF, n = 4; MI-M
-
MNBs/AdhVEGF, n = 4; MI-MNBs, n = 4; MI-Saline, n = 4 
and sham-operated, n = 4]  
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3.13 MNBs/AdhVEGF complexes injection enhanced arteriole density 
MI causes arteriole loss in the ischemic cardiac tissue. Arteriole density was analysed by 
immunohistochemical staining (Figure 27 A). Indeed, in MI treated groups, hearts showed 
reduced densities of small (diameter < 50 μm) arterioles. Conversely, cardiac arteriole 
density was preserved in the border zone of the LV in the MI-M
+
MNBs/AdhVEGF group, in 
which hVEGF was overexpressed in the heart 4 weeks after MI. (Figure 27 B). 
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Figure 27: Intravenous MNBs/AdhVEGF administration induced an increase of arteriole 
density 4 weeks after MI. (A) Representative α SMA staining at the border area of the 
infarcted myocardium. (B) Arteriole density at border zone was significantly higher in the 
MI-M
+
MNBs/AdhVEGF group compared to other MI treated groups. Data are mean values ± 
SEM. # P < 0.05 versus MI-saline, ζ P < 0.05 versus MI-MNBs and τ P < 0.05 versus MI-M-
AdhVEGF. (A) Scale bar = 50 µm. [MI-M
+
MNBs/AdhVEGF, n = 4; MI-M
-
MNBs/AdhVEGF, n = 4; 
MI-MNBs, n = 4; MI-Saline, n = 4] (Figure 27 quoted from [
173
]) 
 
3.14 AdhVEGF expression in the host connective tissue 
In the experiment described below, the magnet was fixed between the third and fourth ribs. 
This caused inflammatory infiltration of macrophages and connective tissue was formed due 
to a substance foreign to the body of the rat (the magnet). Connective tissue mainly contains 
additional cells, such as lymphocytes, fibroblasts, and matrix proteins, e.g. collagen (Figure 
28 A). The connective tissue was tested for hVEGF expression. However, there was little 
hVEGF expression in the MI-M
+
MNBS/AdhVEGF group and the MI-M
-
MNBS/AdhVEGF group 
(Figure 28 B). 
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Figure 28: Magnetically controlled gene expression in connective tissue after systemic 
infusion of MNBs/AdhVEGF. (A) Connective tissue (B) Real-Time PCR analysis for hVEGF 
gene expression in host connective tissue in the MI-M
+
MNBs/AdhVEGF group and MI-M
-
MNBs/AdhVEGF group. There was no significant difference between the two groups.  Data are 
mean values ± SEM. (A) Scale bar = 5 mm; (B) Scale bar = 3 mm. [MI-M
+
MNBs/AdhVEGF, n 
= 3; MI-M
-
MNBs/AdhVEGF, n = 3] 
 
3.15 Matrigel injection improved cardiac function 
In the MI-M group, P max, dp/dt max, -dp/dt max, and EF of the infarcted LV were 
improved at baseline condition compared to the MI-PBS group. Hemodynamic 
measurements are summarized in Table 2 
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Hemodynamics of the LV 4 weeks after MI 
Parameter                               Sham                     MI-PBS                   MI-M                      P * 
                                               (n=6)                      (n=11)                     (n=11) 
P max (mmHg) 
dp/dt max (mmHg) 
-dp/dt max (mmHg ) 
EDV (μl) 
ESV (μl) 
SV (μl) 
EF (%) 
HR 
142.67±2.60           124.83±2.40           134.83±2.89           0.141 
10495.83±311.89   4171.17±298.99     5172.33±266.42     0.031 
9811.83±323.28     3260.00± 329.04    4175.00 ±200.96    0.039 
211.17±8.51           288.17±19.82         266.67±16.77         0.426 
70.50±4.92             183.00±21.23         155.50±14.75         0.312 
150.33±4.76           105.17±7.01           111.16±4.46           0.390 
66.33±2.29             33.00±3.31             41.67±1.92             0.046 
399.50±5.04           360.83±6.25           392.00±7.02           0.007 
 
Table 2：Values are represented as Mean ± SEM, * P < 0.05 versus MI-M, P max,  
maximum pressure; dp/dt max, peak rate of maximum pressure rise; -dp/dt max; peak rate of 
maximum pressure decline; EDV, end diastolic volume; ESV, end systolic volume; SV, 
stroke volume; EF, ejection fraction; and HR, heart rate. Table 2 quoted from [
180
]) 
 
3.16 Matrigel injection increased infarct wall thickness 
LAD ligation consistently resulted in MI, exhibiting typical histological remodelling. 
Representative heart sections (4 weeks after MI) in different groups are shown in Figure 29. 
Although the infarct sizes were not significantly different between the MI-PBS group and the 
MI-M group, left wall thickness was significantly higher in MI-M group compared to the MI-
PBS group. (Figure 29 B). 
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Figure 29: (A) Representative heart cross sections stained with Sirius Red (red, fibrosis) and 
Fast Green (green, myocyte) from rats. (B) Infarct wall thickness was significantly increased 
in the MI-M group compared to the MI-PBS treated group. Data are mean values ± SEM. * P 
< 0.05 versus MI-M. (A) Scale bar = 3 mm. [MI-M, n = 10, MI-PBS, n = 6] (Figure 29A 
redrawn after [
180
]; Figure 29B quoted from [
180
]) 
 
3.17 Matrigel injection enhanced capillary density 
Capillary density was evaluated by immunohistochemical staining with anti-CD31 antibody 
(Figure 30 A). Compared to the MI-PBS group, The MI-M group showed a higher capillary 
density in the border zone 4 weeks after MI. (Figure 30 B).  
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Figure 30: Local matrigel injection induced angiogenesis 4 weeks after MI. (A) 
Representative anti-CD31 staining at the border zone of the infarction. (B) Capillary density 
at the border zone of the LV was significantly higher in the MI-M
+
MNBs/AdhVEGF group 
compared to other MI treated groups. Data are mean values ± SEM. * P < 0.05 MI-M versus 
MI-PBS. (A) Scale bar = 50 µm. [sham, n = 6; MI-PBS, n = 6; and MI-M, n = 6] (Figure 30A 
redrawn after [
180
]; Figure 30B quoted from [
180
]) 
 
3.18 Matrigel injection increased CD34+ and c-kit+ cell recruitment 
C-kit+ and CD34+ stem cell homing after matrigel injection was evaluated by 
immunohistochemical staining (Figure 31 and Figure 32). The c-kit+ stem cell number was 
significantly increased in the MI-M group compared with the MI-PBS group (Figure 31 B). 
Similarly, there were a markedly higher number of CD34+ cells in the MI-M group 
compared to the MI-PBS group (Figure 32 B). 
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Figure 31: Local matrigel administration improved the homing of c-kit+ cells. (A) 
Representative immunohistochemical staining for c-kit+ cells in three groups. C-kit+ cells  
were detected at the border zone 4 weeks after MI. (B) The number of c-kit+ cells in the MI-
M group was significantly increased than in the MI-M group, and only few c-kit+ cells can 
be detected in the sham group. Data are mean values ± SEM. * P < 0.01 versus MI-M. (A-C) 
Scale bar = 250 µm; (D) Scale bar = 50 µm. [MI-M, n = 5; MI-PBS, n = 5, sham n = 5]. 
(Figure 31A-D redrawn after [
180
]; Figure 31E quoted from [
180
]) 
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Figure 32: Local matrigel administration improved the homing of CD34+ cells. (A) CD34+ 
cells were detected at the border zone 4 weeks after MI. (B) The number of CD34+ stem 
cells in the MI-M group was significantly increased compared to the MI-PBS group. Data are 
mean values ± SEM. P < 0.01 versus MI-M. (A) Scale bar = 250 µm; (B) Scale bar = 50 µm 
[MI-M, n = 5; MI-PBS, n = 5]. (Figure 32A-B redrawn after [
180
]; Figure 32C quoted from 
[
180
]) 
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4    Discussion 
4.1 MNBs/AdhVEGF complexes for cardiac repair 
In the present work, a new concept of magnetofection by employing MNBs/Ad complexes 
was introduced. In vitro, the MNBs/Ad complexes’ transduction efficacy and cytotoxicity in 
HUVECs was optimized, and the physical and chemical properties of MNBs/Ad complexes 
were characterized. Attachment of Ad to MNBs was complete at the optimal binding ratio. 
Moreover, at this binding ratio, higher transduction efficiency and comparatively lower 
cytotoxicity was achieved by MNBs/Ad complexes guided by external magnetic force. In 
addition, therapeutic genes introduced via MNBs/Ad complexes were expressed only in the 
defined area by magnetic guiding. In vivo, in a rat MI model, an epicardial magnet attracted 
transduction with a reporter gene, GFP or a therapeutic gene, hVEGF in the injured cardiac 
tissue successfully after systemic delivery of MNBs/Ad complexes (Figure 33). 
Overexpression of hVEGF promoted capillary and arteriole densities, reduced fibrosis, 
decreased left ventricular wall thinning, increased hemodynamic parameters in both systole 
and diastole, and thus improved cardiac functional recovery 
173
. 
 
 
 
 
 
 
 
 
Figure 33: Schematic of MNB based AdhVEGF targeting in vivo. Full gray rings indicated the 
lines of magnetic flux due to the applied magnet. Figure 33 redrawn after [
143
]) 
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Due to MI, the ischemic myocardium can secrete a large number of cytokines including IGF-
1, bFGF, and VEGF for angiogenesis and functional recovery of the heart. Angiogenesis and 
neovascularization are essential for supplying necessary oxygen and nutrients for wound 
healing. Moreover, VEGF is thought to play a key role in angiogenesis and wound healing. 
VEGF may regulate multiple biological functions of endothelial cells including increased 
production of vasoactive mediators, enhanced expression of components of the thrombolytic 
pathways, inhibition of thrombosis, hypotension and vasorelaxation 
131, 182
. A number of 
proteins belong to the VEGF family including VEGF A, B, C, D, E, and placenta growth 
factor. Alternative splicing of human VEGF mRNA from a single gene containing eight 
exons gives rise to five different isoforms consistent of 121, 145, 165, 189 and 206 amino 
acid residues 
132, 183, 184
. It is well known that VEGF strongly stimulates the activity of 
extracellular MAPK and PLC –γ pathway and activation of this pathway plays an important 
role in the stimulation of endothelial cell proliferation as well as for neovascularisation 
122-125
. 
VEGF can also inhibit endothelial cell apoptosis and promote the formation of new 
capillaries by triggering anti-apoptosis kinase pathway PI3K. In addition, VEGF may 
stimulate nitric oxide production which is important for anti-thrombosis and vascular 
protection. Yet, under ischemic conditions, the support by VEGF expression is not sufficient 
to form a functional capillary bed network in the ischemic zone to satisfy the demand of 
tissue growth concerning contractile compensation and greater request of hypertrophied 
myocardial cells. Thereby, the strategy consisted of the systemic delivery of Ad which 
encoded VEGF, so that a higher expression level of VEGF could be reached, which would be 
sufficient to stimulate successful neovascularization and heart functional recovery. However, 
in vivo, therapeutic gene expression in the ischemic cardiac tissue is very low after systemic 
administration of VEGF. Therefore, in this work tightly coupled MNBs/Ad complexes by 
utilizing the high affinity of the biotin-streptavidin bond were developed. The MNBs/Ad 
complexes were used to control selective hVEGF over-expression in the ischemic 
myocardium and, thus, enable improved cardiac function.   
 
In vitro, the coupling ratio of Adluc to MNBs was optimized. At 16 µl MNBs, 8 ×10
7
 pfu Ad, 
and a MNBs/Ad ratio of 2, the MNBs/Ad complexes achieved peak transduction efficacy and 
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comparatively lower cytotoxicity in HUVECs. The highest transduction efficacy was 50 fold 
higher than that of Adluc alone. In line with these results, several other groups showed that in 
vitro, magnetofection can increase the sedimentation of the MNB-based complexes by 
external magnetic force, to further enhance transfection efficiency and to target the 
transfection. Pandori et al. 
144
 utilized the tight interaction between streptavidin and its ligand 
biotin to tether Ad to microbeads, and the conjugates improved the transduction efficacy in 
multiple cell lines. Moreover, concerning paramagnetic properties, the location of Ad 
infections was precisely controllable by a directed magnetic field. In addition, in the work of 
Hofmann et al., 
145
  positive and negative charges were used to bind MNPs to LVs. The 
MNPs/LVs complexes increased viral gene transfer dramatically and the complexes could be 
positioned at specific areas. There are two possible mechanisms of enhanced transduction 
efficacy. Firstly, the MNBs/Ad complexes may sink in the medium because of guiding by 
magnetic force, which would allow Ad to be concentrated on the surface of the cells.  The 
magnetic force may function as an anchor to hold Ad in proximity of the cell surface, so that 
Ad membrane fibre proteins may attach to cell membrane receptors for Ad more easily. 
Secondly, as MNBs are rapidly taken up by cells, it is a possibility that the much more 
MNBs/Ad complexes can be endocytosed by the cells, thus enhancing transduction efficacy 
144
. Furthermore, cellular viability and phenotype of MNBs/Adluc complex transduced 
HUVECs were tested. After transduction, the viability of HUVECs remained over 80% and 
transduced cells did not change their morphology compared with untransduced cells. This 
result was consistent with the work of Myokhayly  ´ group who also demonstrated 
magnetofection to have but few influence on transfected cells 
185
. The average diameter of 
MNBs/Ad was assessed by ZetaPALS analyzer. In this experiment, two significantly 
different groups of particles were observed. One group consisted of free Ad (size at 100-
200nm) and the other corresponded to MNBs/Ad complexes (size at 300-600nm).  Results 
indicated that by increasing MNBs doses, the MNBs/Ad complex group became enlarged 
whereas the signal corresponding to free Ad was diminished. Finally, an almost constant of 
100% was reached by a MNBs dose of 16µl. The optimal binding ratio for generating 
effective, non-toxic MNBs/Ad complexes was: 16µl MNBs, 8 × 10
7
 pfu Ad, and a MNBs/Ad 
ratio of 2. This result was consistent with the MNBs/Ad transduction experiment, a fact 
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which may explain that the higher saturation of MNBs/Ad did not lead to a higher 
transduction efficacy. 
 
Physiologically relevant models 
186
 have been used to examine the theoretical aspects of 
magnetic targeting in vivo. For most magnetic carriers, a magnetic flux density (field strength) 
at the target site of the order of 200-700 mTesla was proven to be necessary in order to 
capture particles flowing in the blood stream. Additionally, the results indicated that magnet-
based therapeutic gene delivery is likely to be more effective for target sites that are close to 
the body surface or situated in regions of relatively slow blood flow. Generally, super-
paramagnetic iron oxide nanoparticles are used as magnetic components of the complex, as 
this type of particles exerts a strong magnetic force. The other advantage of super-
paramagnetic particles is their low tendency to aggregate due to magnetic dipole interactions 
in the absence of a magnetic field 
143
. Concerning the relevant in vivo experiment, in a rat MI 
model, 7 days after intravenous injection of MNBs/AdhVEGF or MNBs/AdGFP complexes, an 
epicardially placed magnet (1000 m Tesla), successfully accumulated the complexes, which 
resulted in strong reporter gene (GFP) as well as therapeutic gene (hVEGF) expression in the 
ischemic zone of the heart. Higher levels of hVEGF or GFP gene expression were detected 
by Real-Time PCR and immunohistochemical staining in the ischemic myocardium of the 
MI-M
+
MNBs/Ad group. These results were consistent with previous studies: Cheng and his 
group 
187
 successfully labelled cardiosphere-derived cells with superpara-magnetic 
microspheres. When magnetic force (1000 m Tesla) was applied, cells were visibly attracted 
towards the magnet and accumulated around the ischemic zone compared to the group 
without magnet application. Results confirmed that magnetic targeting enhanced cell 
retention (at 24 hours) and engraftment (at 3 weeks) 3 fold compared to the non-targeted 
group. Moreover, echocardiography analysis proved that a significant heart function 
improvement as well as a decrease in left ventricular remodelling occurred in the magnetic 
targeting group. Moreover, Li et al. 
188
 coupled magnetic MNBs to DNA and PEI. In a 
murine model, a magnet placed epicardially effectively attracted MNBs/DNA/PEI complexes 
to the heart, resulting in strong reporter and therapeutic gene expression in the myocardium. 
Additionally, Hofmann et al. 
145
 used charge to attach MNPs to LVs, and application of and 
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external magnetic field significantly guided LVs transduction to the vascular system. 
Experimentally, the MNBs/AdlacZ and MNBs/AdGFP complexes could be directed to specific 
locations defined by external magnets both in vitro and in vivo. Hence, MNBs/Ad complexes 
may acquire an important role for confined therapeutic gene expression targeted towards 
tissues or organs. In combination with viral agents, the complexes may avoid spreading of 
viral particles in surrounding tissues and, therefore, limit uncontrolled infection of untargeted 
organs. Moreover, the complexes can limit the virus load necessary for effective transduction 
144
. 7 days after MI surgery, the magnet was surrounded by connective tissue. However, 
hVEGF expression was very few in the connective tissue by Real-Time PCR evaluation. This 
result also confirmed external magnetic field can restrict gene expression to the targeted 
region. 
 
In addition, in present experiments, the results proved that MNBs/AdGFP were successfully 
targeted towards the ischemic heart area and the transduced genes were expressed locally at 
different time points. It also proved that magnetic gene trapping from the blood circulation 
was fast and effective. Normally, one cycle of systemic blood circulation which transports 
oxygen-rich blood away from the heart, to the rest of the body, and returns oxygen-deleted 
blood back to the heart is completed in less than 3 minutes. So, theoretically, MNBs may be 
attracted by external magnetic force in a short time (less than half hour). Sato’s group 189 
performed a common rat carotic artery injury model and administrated endothelial progenitor 
cells/super-paramagnetic nanoparticle complexes in the common carotic artery under 
magnetic guiding for 10 minutes. They found a marked increase in cell retention at the site of 
injury at 24 hours after implantation in vivo. In the MNPs/LV transduction experiments 
performed by Hofmann and his group 
145
, the complexes were also injected into the carotid 
artery via catheter and a NdFeB magnet was placed at the right abdominal wall close to the 
liver for 30 minutes. Again, the complexes were found to be redistributed significantly to the 
liver 6 days after injection, as compared to the non-targeted group. For future use in the clinic, 
it is highly probable that the technique of MNB-based gene therapy will work with 
application of  the magnet for a short time during heart surgery. 
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In animal experiments and clinical trials, delivery of  VEGF gene or protein showed a great 
potential for improving cardiac function after MI 
139, 190-194
. In this study, hVEGF gene has 
been proven to enhance vascular network formation by HUVECs in vitro and stimulate 
endothelial cell proliferation, promoted angiogenesis, and improved right ventricular 
performance in vivo. So far, the cell types mainly overexpressing VEGF in vivo were not 
clear. In order to gain knowledge on the mechanism of VEGF-enhanced ischemic heart 
regeneration, the VEGF expression of endothelium as well as myocardium was analyzed and 
the results demonstrated that hVEGF systemic administration of AdhVEGF improved right 
ventricular performance. hVEGF expression in myocardium was detected by Real-Time PCR 
and immunohistochemical staining after 7 days MI in the MI-M
+
MNBs/AdhVEGF transduced 
rat group, showed hVEGF gene expression in the endothelium. This result indicated that 
AdhVEGF could successfully transduce endothelial cells in vivo. It is well known that VEGF 
strongly stimulates endothelial cell proliferation and induces endothelial nitric oxide synthase. 
The important functions of these two mediators include neovascularization, inhibition of 
platelet accumulation and leukocyte adhesion 
121, 195
. In addition, a significant increase in 
capillary and arteriole densities occurred in the border zone of ischemic heart. This is 
consistent with previous reports that hVEGF induced neovascularization and angiogenesis 
around the infarct zone 
194, 196, 197
. Moreover, I found AdhVEGF can penetrate the vessel wall 
and transduce cardiomyocytes to a low extent. The group of Guerrero et al. 
196
 showed that 
VEGF gene therapy promoted cardiomyogenesis after MI. Furthermore, the groups of 
Laguens and Vera proved that an increased number of mitotic cardiomyocytes were detected 
in sheep and pig MI models after overexpression of VEGF gene 
194, 197
. The increase of 
capillary and arteriole density, and cardiomyogenesis may act jointly to cause the LV 
functional improvement in hVEGF-treated animals.  
 
VEGF gene delivery for therapeutic angiogenesis is of great importance in clinical trials. 
Post-infarction, a mature scar is formed which contains collagen I and collagen III as well as 
some newly formed microvessels. However, the neovascularization is insufficient to support 
the contractility of the ischemic myocardium. The aim of therapeutic angiogenesis is to 
induce the formation of a collateral blood supply, which allows for a sufficient support of the 
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ischemic tissue with oxygen and nutrients, and thus to allow for repair of the myocardial 
damage. Especially VEGF has a high potential to induce angiogenesis. To date, over one 
thousand patients with ischemic heart disease who are taking part in clinical trials assessing 
the functions of recombinant angiogenic growth factors or therapeutic genes encoding for 
growth factors, including VEGF 
135, 136
. In all these clinical trials evaluating angiogenesis 
therapy for ischemic heart disease, intramyocardial 
140, 198
 and intracoronary 
141
 deliveries are 
the two main ways of delivery for gene transfer. However, intravenous delivery is only used 
as an auxiliary method combined to intracoronary delivery 
199
.  As intracoronary injection 
has certain advantages such as cardiac specific delivery, this technique has been widely used 
in most research projects as well as in clinical trials of gene and cellular therapies. 
Concerning intracoronary delivery of vascular growth factor genes, Laitinen et al. 
200
 were 
the first to test intracoronary injection of AdVEGF in patients treated with PCI. They found that 
myocardial perfusion significantly increased within the AdVEGF treated group. This result also 
indicates that intracoronary infusion may enhance transduction efficacy, and increasing the 
efficacy of Ad might be of importance for the clinical outcome 
135
. Furthermore, the 
intracoronary injection of recombinant VEGF protein was initially tested in a small phase I 
clinical trial in patients suffering from severe CAD for whom conventional surgical 
procedures were not suitable. The outcome has proven that intracoronary infusion of 
recombinant VEGF-A protein is safe and well tolerated and may be a promising treatment to 
improve myocardial perfusion and exercise capacity of patients 
201, 202
. However, some 
research groups 
203-205
 showed that the uptake of genes by the myocardium following 
intracoronary infusion was not very high, in contrast to that in non-cardiac filter organs 
including liver and spleen. A double blind placebo-controlled Phase II trial was designed to 
evaluate safety and efficacy of combined intracoronary and intravenous infusions of VEGF 
protein for angiogenesis after MI 
199
. A total of 178 patients were randomised to receive a 20-
minute intracoronary infusion of placebo or VEGF followed by intravenous deliveries on 
days 3, 6 and 9, with evaluation after 2 and 3 months. The study has proven that the treatment 
strategy was safe and well tolerated, but it was not possible to detect any improvement in the 
VEGF protein compared to the placebo group. Overall, the disappointing results from clinical 
trials of angiogenic cytokine treatment may be due to an insufficient concentration of the 
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growth factors within the myocardium. Clinical trials have proven that only 3%-5% of the 
angiogenic cytokines which have been delivered by intracoronary infusion were taken up into 
the cardiac tissue 
135, 189
. In addition, intracoronary injection carries the risk to affect the 
endothelial lining and vessel wall with the effect of potential complications 
206
 .  
 
Direct intra-myocardial injection is another main method for therapeutic gene delivery. In 
broad terms, the advantages of this approach include the ability to target delivery of 
therapeutic agents to one or more specific regions within the myocardium. By intracoronary 
injection, a large amount of therapeutic agents will not be taken up from the vascular 
compartment of the heart during their first pass, and therefore they will be delivered to other 
tissues 
207
. Nevertheless, intra-myocardial injection has the potential to achieve higher local 
concentrations at target zones, such as areas of infarction and peri-infarction, with a 
simultaneous reduction of the required dose. Several research groups 
198, 208, 209
 have proven 
that intramyocardial infusion was successfully performed in animal models. Maca et al. 
208
 
found that after direct injection of Ad containing VEGF into ischemic myocardium of pig 
hearts, both myocardial perfusion and function were significantly improved. Furthermore, the 
safety and efficacy of adenoviral transduction with the VEGF gene was tested in several 
clinical trials 
140, 198, 209
. In a study undertaken by the group of Rosengart 
140
, AdVEGF was 
injected intramyocardially into an ischemic area as an add-on to conventional CABG (n = 15) 
or as stand-alone therapy via a minithoracotomy. No evidence of systemic or cardiac-related 
adverse effects was found and no adenovirus was detected in peripheral blood samples. A 
trend towards improved myocardial perfusion and reduced angina pectoris was observed by 
angiography. Although of potential clinical importance, this approach for intramyocardial 
delivery has several limitations. Firstly, considerable risk and expense is associated with the 
invasive nature of this procedure. Secondly, even if mechanical function is improved, some 
studies have raised the question whether deleterious secondary effects of heterogeneous 
integration may occur, such as a risk of arrhythmia 
210, 211
.  
 
Intravenous injection may provide a non-invasive alternative that would be tolerated well by 
patients with MI. However, most of the genes delivered intravenously are expressed in the 
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liver and only a very small portion, normally < 0.5% of the dose, is taken up by the 
myocardium 
189, 212
. Thus, the expression rate of the angiogenic gene in the heart may be 
insufficient to support angiogenesis. In the context of intravenous gene therapy, increasing 
cardiac specificity including the use of cardiac specific promoters and viral vectors that 
provide relative cardiac tropism is one of the possibilities to solve this problem. As an 
alternative approach, in our group, a novel technique of magnetic force-enhanced gene 
delivery in cardiovascular system was developed which has a great potential for rapid and 
efficient transduction. 
 
Ad can efficiently infect and express their genes in a wide range of cell types and tissues 
containing dividing and non-dividing cells, and do not insert into host chromosomes. Still, 
one of the main disadvantages consists in the fact that Ad may cause a strong immune 
response. The inflammatory response is characterized by an increase of inflammatory 
cytokines and stimulation of inflammatory cell types such as macrophages, neutrophils, and 
CD8
+ 
T cells. In the presented work, I used a recent type of Ad which were deficient in the 
E2, E3, and E4 regions, resulting in reduced immunogenicity 
213
. I still found an 
enhancement of CD8
+ 
T cells mobilized to peripheral blood in the MI-
Magnet
+
MNBs/AdhVEGF group 7 days after intravenous injection. It is well known that CD8
+
 
T cells are believed to be directed against the viral infections and CD8
+
 T cells may secrete a 
series of apoptosis and necrosis-inducing cytokines including interferon-γ, TNF-α and 
interleukin-2 
214, 215
. 
 
Another obvious drawback was the limited duration of Ad medicated transgene expression, 
because the adenoviral genome does not insert into host cell chromosomes during the 
infection. The experiment of transgene expression persistence showed that the effect of Ad 
mediated gene delivery lasted 4 weeks with a decline towards the end of that time period. 
Therefore, long-term expression and low immunogenicity may be better achieved by other 
gene carriers. AAV have several advantages including low cytotoxicity and immunogenicity, 
and long term expression. Normally, growth of collateral capillaries and arteries requires 
long term transgene expression 
216
. Especially AAV 8 and 9 are superior to other serotypes in 
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transducing myocardium and endothelium 
217, 218
.  Therefore, AAV are ideal candidates for 
non-invasive gene transfer to the heart, and MNBs/AAV have the potential to efficiently 
induce therapeutic gene expression in the heart for cardiac regeneration . 
 
In summary, the data presented above showed that MNB-assisted gene transduction may 
achieve not only high efficacy and comparatively low cytotoxicity, but also targeted gene 
expression.  Importantly, in vivo, therapeutic gene expression in the injured myocardium by 
external magnetic field guiding, can promote neovascularization, reduce infarct wall 
thickness and improve cardiac function. So far, current experiments may serve as a proof-of-
concept in a small animal model only. In the next step, additional data on MNB-based 
therapeutic transduction for MI, such as the required strength and duration of magnetic force 
in a large animal model, is important to advance the process of clinical translation. In 
summary, MNB-assisted Ad transfer, positioning and therapeutic gene expression is a 
promising technique for combined gene or cell therapies. It enables systemic administration 
of therapeutic genes and magnet-based, site-directed targeting.  
 
4.2 Matrigel for cardiac repair 
In the present study, local administration of matrigel into the ischemic heart significantly 
improved heart function, including systolic and diastolic blood pressure and EF 4 weeks after 
rat MI. Injection of matrigel did not reduce infarct size but markedly enhanced left 
ventricular wall thickness. Moreover, intracardiac injection of matrigel increased capillary 
density. Finally, significantly higher c-kit+ and CD34+ stem cell recruitment to the ischemic 
heart occurred after matrigel treatment  
180
. 
 
In the experiments, the c-kit+ cell number was much higher in the MI-M group than in the 
MI-PBS group. It is well known that the SCF and c-kit tyrosine kinase receptor ligand plays 
an important role in promoting the homing of c-kit+ stem cells (also positive for CD34). SCF 
expression is upregulated in the ischemic cardiac tissue after MI. Overexpression of SCF 
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increases the c-kit+ cell mobilization towards the injured myocardium following the SCF 
gradient 
71-74
. Moreover, after the c-kit receptor is stimulated by SCF, c-kit+ cells can co-
express GATA4, Nkx2.5, and myocyte-specific enhancer factor 2C which may promote the 
c-kit+ cells’ potential to differentiate into cardiomyocytes 219. In addition, Wnt/β-catenin 
signalling may occur in cardiac progenitor c-kit+ cells to stimulation of cardiomyocytes self-
renewal through proliferation, maintaining the cardiomyocyte turnover in the heart after cell 
loss 
220
. Several experiments confirmed that c-kit+ cell therapy may enhance the contractile 
function, promote angiogenesis and restore cardiac function 
211, 221-223
. These results were 
consistent with the findings in current experiments. Thereby, matrigel which contains various 
growth factors such as bFGF, PDGF, and TGF-β may support the homing c-kit+ stem cells 
with nutrients, thus  promoting cell proliferation, inhibiting apoptosis, further improving 
neovascularization and cardiac function. Therefore, it is possible that the observation of an 
increased number of c-kit+ cells in cardiac tissue can be attributed to the support of matrigel. 
A large number of hydrophilic natural or synthetic biopolymers can be applied for tissue 
engineering or drug delivery due to their flexibility, which is very similar to natural tissue 
224-
226
. Currently, biopolymers can be used in ischemic heart therapy 
227
. The use of biopolymers 
alone can increase thickness and stabilizing of ischemic myocardium. When used as scaffolds, 
biopolymers may be used to deliver a diversity of stem cells or therapeutic molecules such as 
growth factors to improve cardiac function 
174, 228
. Fibrin as a natural cross-linked 3-
dimensional biopolymer has been widely used for cardiac therapy 
227, 229-231
. In a rat MI 
model, several groups have proven that intromyocardial administration of fibrin biopolymer 
one week after MI may improve cardiac properties, decrease infarct size, and increase 
neovascularization 
227, 229, 230
. In a porcine MI model, Mukherjee et al. 
231
 successfully 
injected biopolymers locally, including both fibrin and alginate, a bioinert material, to 
prevent LV remodeling after MI. Additionally, chitosan as a linear polysaccharide has been 
explored for MI therapy with a view to its biocompatibility and biodegradability 
232
. Lu et al. 
228 
showed that in a rat MI model, local delivery of chitosan biopolymer can enhance diastolic 
and systolic indexes, preserve the geometric dimensions LV, and decrease infarct wall 
thickness 
174, 233
.  
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Matrigel as a commercial biopolymer is derived from base membranes. Since matrigel is a 3-
dimensional scaffolding matrix, it may also prevent ischemic heart remodelling by 
supporting the structure of left ventricular wall.  The conventionally used rigid or solid 
matrices disrupt the continuity of the cardiac architecture, and create excess shear stress in 
the ischemic myocardium 
234
. However, matrigel remains liquid until the intracardiac 
injection, and its 3-dimensional matrix may adapt to the geometry and structure of the left 
ventricular space. Kofidis’ group 176 proved that matrigel was sufficient to improve left 
ventricular wall thickness 2 weeks after MI and to prevent deterioration of cardiac function. 
This result was consistent with current findings, which indicated that local matrigel 
administration may increase left ventricular wall thickness. The structural enhancement of 
the injured area of the LV may be the mechanism of functional cardiac tissue improvement.  
Additionally, intramyocardial injection of matrigel significantly increased capillary density 
and promoted angiogenesis. FGF is a pro-angiogenic growth factor which may promote the 
formation of new vasculature 
174
. Several groups reported that local injection of FGF 
increased capillary density and attenuated the LV remodelling 
235, 236
. PDGF delivery 
recruited smooth muscle cells to support immature neovascularization. Hao et al. 
169
 showed 
that the dual release of the growth factors of VEGF and PDGF in the ischemic myocardium 
significantly increased the number of α-SMA containing blood vessels around the injection 
site 4 weeks after MI. Matrigel contains pro-angiogenic factors including both bFGF and 
PDGF may, thus, improve the functional recovery by promoting angiogenesis.   
 
Matrigel plays an important role in MI therapy, but it also has some disadvantages. Matrigel 
is derived from the basement membrane and secreted by mouse sarcoma. Also, its 
components are not well defined till now and it has the potential to promote tumor cell 
invasion 
176
. Although, in the present work, I did not find tumor formation in the myocardium, 
the next step should focus on the biological mechanisms of matrigel, especially clinically 
relevant parameters. At present, matrigel shows some merits better than other types of 
biopolymers.  
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In summary, matrigel as a biopolymer was able to adopt the behavior of the ischemic cardiac 
environment, which may support the host tissue. Additionally, local injection of matrigel 
after MI recruited c-kit+ and CD34+ stem cells, promoted angiogenesis, reduced left 
ventricular wall thinning, and improved heart function. In further experiments, this type of 3-
dimentional matrix may be used as a vehicle for the delivery of therapeutic stem cells to the 
injured heart. The appropriate matrix environment may improve cell retention and 
engraftment in the damaged myocardium suffering from ischemia. Matrigel alone or matrigel 
based cell therapy offers therefore a great potential in MI therapy.  
 
4.3 Biotechnological techniques for myocardial angiogenesis and 
functional recovery 
 
Gene therapy offers new possibilities concerning the restrictions of current treatment for 
cardiac ischemia. Continuous therapeutic gene expression at targeted sites may be used to 
regain the myocardial functions that are impaired during MI progression. VEGF is one of the 
best candidates for induction of therapeutically effective angiogenesis in the ischemic heart. 
A variety of animal MI models have proven that VEGF gene therapy may increase 
neovascularization 
237
, promote vessel formation 
238
, significantly induce angiogenesis, and 
improve cardiac functional properties 
237, 239
. Meanwhile, VEGF gene therapy for myocardial 
ischemia significantly improved cardiac function in a clinical trial 
240
. Magnetofection as a 
novel gene delivery technique can minimize the vector dose but maintain efficiency while 
confining the risk to the target area 
142, 144, 241
. With application of a permanent magnet, 
magnetic complexes may migrate along the high magnetic gradient fields in vitro and in vivo 
189, 242
. In current experiments, a new technique of magnetofection was utilized, MNB based 
VEGF gene delivery. This therapy successfully increased angiogenesis and enhanced cardiac 
function after MI. 
 
Biopolymers such as matrigel, fibrin, and collagen have been developed and widely studied 
as translatable materials for MI therapy 
164, 176, 229, 243
. Especially matrigel, as a natural 
biopolymer, is able to adopt the geometry of the host tissues. Furthermore, matrigel may 
                                                                                                                                                                                         
                                                                                                                                                                                      Discussion                                                                                                                                                                                                                                                                            
88 
 
serve as vehicle for delivery of biologically therapeutic molecules 
183, 195
. In present 
experiments, the new technique of local matrigel delivery offered a less invasive and more 
effective approach for MI therapy. Intramyocardial administration of matrigel promoted 
neovessel formation, increased capillary density, and preserved LV remodeling. 
 
Future work will serve to further analyze and evaluate the various new techniques for cardiac 
disease treatment and focus on clinically relevant parameters, such as the selection of suitable 
animal models and appropriate modes of delivery. Knowledge gained from such work may 
lead to a clear illustration of the effects of new biotechnological approaches for the treatment 
of patients with ischemic heart disease. 
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5    Conclusions  
 
The objective of the present work was the development of novel biomedical techniques for 
cardiac regeneration employing targeted gene transfer and biomaterial-based tissue 
engineering. Using a rat model of MI, the therapeutic effect of stable magnetic field-guided 
MNBs/AdhVEGF complexes was evaluated on the one hand and intracardiac matrigel injection 
on the other hand. Based on my experimental results, the following conclusions can be drawn: 
 
Targeted delivery of human VEGF gene via complexes of magnetic nanoparticle-
Adenoviral vectors enhances cardiac regeneration 
 
In this study, stable MNBs/Ad complexes were developed and systematically administered 
encoding hVEGF under external magnetic guidance for cardiac regeneration.  
 
This research demonstrated that (1) High affinity and effective binding properties of biotin 
and streptavidin can form extremely stable magnetofection complexes. (2) The MNBs/Ad 
complexes could be directly targeted towards specific locations defined by an external 
magnet. (3) In vivo, magnetic force effectively targeted VEGF gene expression to the 
ischemic zone of the heart. VEGF expression promoted angiogenesis and improved heart 
function.  
 
It follows, therefore, that systemic administration of MNBs/Ad complexes guided by external 
application of magnetic force may be a useful, non-invasive, gene-based therapeutical 
approach to enhance post–infarction myocardial repair. 
 
Intracardiac injection of matrigel induces stem cell recruitment and improves cardiac 
functions in a rat MI model  
 
In this study, intracardiac delivery of matrigel recruited CD34+ and c-kit+ stem cells, 
promoted angiogenesis and improved cardiac function after ischemia.  
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Findings indicated that: (1) Matrigel contained ECM components which may prevent 
negative remodelling of the myocardium by providing three-dimensional support to the 
infarcted area. (2) Matrigel contained various growth factors and a natural micro-enviroment 
for the homing of c-kit+ and CD34+ cells which may provide additional nutrients to the 
ischemic myocardium, promote cell proliferation and mediate angiogenesis.  
 
Hence matrigel as a three dimensional matrix is able to support host tissue, influence stem 
cell recruitment as well as survival and cell proliferation. In present study, matrigel therefore 
shows promising results to treat MI and human derived “matrigel analogs” may have a great 
potential for cardiac regeneration.  
  
Perspectives on the future of MI therapy  
 
Future large animal studies and finally clinical trials with magnetic guiding based angiogenic 
gene therapy or matrigel mediated cardiac protection will help determine whether these novel 
techniques could provide new treatment modalities in patients with ischemic heart disease. 
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